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Abstract"
"
" Pain is a major personal and community burden throughout the world with currently 
limited treatment options for persistent pain due to unacceptable side effects, dependence 
or frank inefficacy. It is necessary to understand the anatomical and molecular pathways 
leading to pain to better cope with the current challenge of treating it. "
" TRPV1 is a ligand-gated ion channel primarily expressed in small fiber sensory 
neurons and is important for the transmission of pain sensation in the nociceptors. TRPV1 is 
activated in response to painful heat and is sensitized through various internal signaling 
mechanisms. The sensitization of this channel has never been studied in a high-throughput 
un-biased approach. We developed a method using primary sensory murine neurons in a 
high-throughput apparatus to examine the sensitization of TRPV1. We applied this method 
to examine sensitization of TRPV1 over a 24-hour period to discover TRPV1 sensitization 
following many different compounds, including bortezomib, a proteasome inhibitor used to 
treat multiple myeloma. This compound frequently causes painful neuropathy in patients. 
The mechanism of this is unknown, even as it is a dose-limiting effect of this important 
cancer treatment. As demonstrated further via traditional cell-focused calcium-imaging 
experiments, bortezomib sensitizes TRPV1 in vitro. These results highlight a hypothetical 
mechanism of the painful aspects of bortezomib-induced polyneuropathy that is TRPV1-
sensitization dependent. More pivotally, TRPV1 hyperfunction could drive a calcium-induced 
toxicity leading to the neuropathy itself. "
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" We additionally investigate experimental approaches for accessing nociceptor inputs 
via optochemical means as discovered in a zebrafish behavioral assay as well as using a 
neuronal silencing strategy to show that histamine-dependent and histamine-independent 
itch are mediated by a separate population of neurons."
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
 iv
Table of Contents!
"
"
"
"
"
"
"
"
"
Tables and Figures vi
Acknowledgements viii
Dedication ix
Introduction 1
Chapter 1: Chemotherapy-induced neuropathy and TRPV1 5
Chapter 2: Kinetic high-throughput imaging of primary sensory neurons 20
Chapter 3: Proteasome inhibition sensitizes TRPV1 in DRG neurons 34
Chapter 4: Photochemical activation of TRPA1 channels in neurons and animals 58
Chapter 5: QX-314 silencing reveals distinct itch-generating sensory neurons 82
Conclusion 103
Appendix 106
 v
Tables and Figures!
"
Table 2.1 - Comparison between mammalian cell line and primary sensory 
neurons.
25
Figure 2.1 - Calcium flux method was established for DRG neurons in a 384-well 
format.
26
Figure 2.2 - Characteristics of plate coverage and activation. 28
Figure 2.3 - High-throughput neurite outgrowth assay. 29
Chart 2.1 - Comparative analysis between traditional and high-throughput imaging 
methods.
31
Figure 3.1 - High-throughput sensory neuron imaging. 42
Figure 3.2 - Unbiased large-scale experiment uncovers the proteasome inhibition 
as potential mechanism for TRPV1 sensitization.
44
Figure 3.3 - Structures of proteasome inhibitors that cause TRPV1 sensitization. 45
Figure 3.4 - 24 hour bortezomib treatment increases strength of response and 
amount of TRPV1+ cells responding.
46
Figure 3.5 - Time dependency of TRPV1 sensitization following bortezomib-
treatment.
47
Figure 3.6 -  TRPV1 mRNA expression levels unmodified following treatment with 
1uM bortezomib. 
48
Figure 3.7 - 100nM bortezomib treatment desensitizes KCl and AITC responses. 50
Figure 4.1 - Identification of optovin, a compound enabling light-mediated neuronal 
excitation.
60
Figure 4.2 - Optovin-treated spinalized preparations respond to light. 63
Figure 4.3 - TRPA1 is necessary and sufficient for the optovin response. 64
Figure 4.4 - Mustard oil and optovin act on the same subset of DRG sensory 
neurons.
65
Figure 4.5 - Optovin has no activity on the hTrpA1 3CK triple cysteine mutant. 66
Figure 4.6 - Remote control of optovin-treated animals. 68
 vi
"""""""" "
"
"
"
"
"
"
"
Figure 5.1 - Co-administration of QX-314 and pruritogens inhibits subsequent 
pruritogen-evoked scratching.
88
Figure 5.2 - Pruritogen and algogen- mediated scratching measured 30 minutes 
after conditioning injections.
89
Figure 5.3 - Distinct primary afferents mediate histaminergic itch and non-
histaminergic itch.
91
Figure 5.4 - Proportional representation of coincident trigeminal cell responses to 
low-dose chloroquine and histamine and their overlapping responsiveness with 
capsaicin and AITC.
94
Figure 5.5 - Venn representation of relative populations of trigeminal and DRG 
neurons defined by their calcium responses to histamine and chloroquine.
95
Figure 5.6 - Selective silencing of nociceptor populations differentially inhibits 
histamine itch and non-histamine itch.
96
Supplementary Figure 2.1 - Demonstration of raw data from FDSS 7000EX 
apparatus.
106
Supplementary Figure 2.2 - Calculation of Z-scores from raw data in FDSS 
7000EX apparatus.
107
Supplementary Figure 3.1 - Top hits from BioMol screen for TRPV1 sensitization. 108
 vii
Acknowledgments!
"
It would have been impossible to do this work without the help of many incredible people. I 
thank Dan Smith, Edward Krupat, Bruce Donoff, Howard Howell, Bjorn Olsen, Peter 
Hauschka, and David Guthrie for early support. My dissertation advisor, Clifford Woolf, has 
cultivated a perfect place to discover and provided invaluable encouragement and direction. 
In the lab, I must particularly thank Ajay Yekkirala. As well I thank Christian von Hehn, 
Cleverton Kleiton Freitas de Lima, Michio Painter, David Roberson, Enrique Jose Cobos del 
Moral, Takao Omura, Alban Latremoliere, Mike Costigan, Cynita Blalock, Rebecca Innis, 
Brian Wainger, Liam Browne, Seungkyu Lee, Sebastien Talbot, Cassidy Mellin, Sun Wook 
Hwang, Lee Barrett, Gabriel Corfas, Robin Kleiman, Seog Bae Oh, David Kokel, Randall 
Peterson, Johnathan Tran, Cara Piccoli, Elizabeth Buttermore, Wardiya Afshar Saber, Isaac 
Chiu, Nader Ghasemlou, Christian Brenneis, Sebastien Talbot, Catherine Ward, Nick 
Andrews, Yung-Chih “Inge” Cheng, Amanda Strominger, Talia Patapoutian, Octavio 
Viramontes, and Navid Soltani for assistance, advice and help in the lab. Additional thanks 
to Mik Rinne for helpful discussion. My dissertation advisory committee: Rachelle Gaudet, 
Gary Yellen and Qiufu Ma, were a great help. I also thank the National Institute of Dental 
and Craniofacial Research for their support through a Ruth L. Kirschstein National Research 
Service Award (DE023033-02)."
"
Many thanks to Jonathan Perrino who served as an excellent coach, my parents, parents-in-
law and siblings who have all supported and encouraged me and to my children who have 
cheered for me. And mostly I thank my wife, Laura. She has been there through it all."
"
"
 viii
Dedication!
"
Dedicated to E, M and Z. Keep discovering. 
 ix
Introduction!
"
Pain is a massive burden, both for individuals and for society. A recent report of the 
economic burden of pain estimated indirect and direct costs at over $500 billion per year in 
the United States1. However, personal, non-financial costs can not even be estimated. 
Activities of daily living are disrupted or altogether stopped. Pain treatment is still 
inadequate. "
"
The network of neurons that senses, transmits and processes painful or noxious stimuli is a 
dynamic system. It helps us respond to the environment appropriately, and it also responds 
to the environment. The cells responsible for initiating nociception are spread throughout the 
body, maintaining sensitive nerve endings to detect harmful substances. These are primary 
sensory neurons. Upon recognition of an offending agent, they pass a signal along to cells in 
the spinal cord, which again relay a message to various cells that traverse the spinal cord 
and go to the brainstem and brain, or sometimes double back immediately along motor 
neuron tracks to affect muscle contraction locally. "
"
The neurons that initiate this response are dependent for their function on discrete 
receptors. These molecular receptors are tiny, but quite effective and include among them 
TRPV1 (Transient Receptor Potential Vanilloid type 1). These molecular receptors 
specifically respond to an array of temperatures, chemical stimuli, and mechanical 
perturbations, initiating a signal which we can interpret with enough resolution to know what 
is hurting us (whether sharp, hot or cold, for instance) and where. "
"
Our system for sensation can be drastically modulated. At times, the pain we feel is 
disproportionate to the insult. Wearing a shirt, for instance, after a bad sunburn can be quite 
painful. Fortunately for us, the painful effects of a sunburn are quite transient. Yet, some 
people suffer from chronic neuropathic pain due to damaged nerves and may experience 
pain much more severe than a sunburn to a typically-innocuous insult. The effects of 
constant or chronic pain are debilitating."
" "
The complexity and variety of natural experience in pain modulation indicates that many 
pathways regulate the perception of pain. Pain can not be treated based on the intensity 
alone, but rather, it needs to be treated based on the actual mechanism. Understanding 
these mechanisms is at the core of my research in the Woolf lab and is an important step to 
properly treating pain. Over the years, careful observations have built a roster of key 
receptors, ion channels, soluble mediators, signaling peptides, enzymes, internal signaling 
pathways, nerve networks, and effector cells in pain biology. Undoubtedly, there are still 
many more to discover. We have explored many of these connections and pathways even 
when not specifically focused on pain because we know that biological systems are 
interconnected. Itch, as an example, is a system that shares common pathways with pain."
"
Lidocaine is a compound used in dental offices around the world as a local anesthetic. Its 
primary mode of action is by crossing into the nerve and blocking sodium channels from the 
inside, preventing the nerve’s ability to relay information. In the lab, we have used a 
compound very similar to lidocaine in its nerve blocking properties with the exception of one: 
it can not get into a nerve on its own. This makes it a useful experimental tool as it will only 
get into nerves that are made susceptible to allowing the compound in, determined by the 
researcher2. Using this approach, we were able to explore the anatomical differences 
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between histamine-dependent and independent itch, showing that these were distinct 
populations of cells3."
"
Understanding the role of cells and pathways in the nervous system has also been studied 
through the use of a technique call optogenetics. Optogenetics utilizes a non-native light-
sensitive receptor to make a nerve active4. One great advantage of this approach is that a 
researcher can use a beam of light to activate one nerve at a time, and by watching the 
downstream effects, come to a conclusion as to what makes that particular nerve important. 
Optopharmacology is a variation on that theme, combining light with chemicals to activate 
native receptors to better understand the role of those receptors in their natural context. We 
developed and characterized an optopharmacological tool to activate an ion channel that is 
important for pain and itch and showed that it works in both fish and mice5. "
"
Being able to better understand how ion channels contribute to the signals leading to pain is 
a fundamental part of pain biology. TRPV1 is important for pain activation and also plays a 
role in itch. It resides in the membrane of a nerve, is opened to allow ions such as calcium or 
sodium to move across that membrane, generating an electrical signal. It opens in response 
to heat, acid and also a chemical in hot chili peppers called capsaicin. "
"
Studying TRPV1 biological function is very important for understanding pain. TRPV1 is 
tuned to become hypersensitive by inflammatory mediators and might become more 
sensitive in other painful conditions such as neuropathic pain caused by chemotherapy 
treatment. To contribute to the current understanding of TRPV1 function, we tried a novel 
approach using primary sensory neurons. We examined these cells in a high-throughput 
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system to take advantage of the natural expression and signaling pathways of TRPV1 in 
these native nerves. "
"
We used this approach to ask more of TRPV1 sensitization, but in an unbiased manner. We 
discovered that TRPV1 function is modulated in response to several different 
chemotherapeutic agents, including some that have never previously been reported to 
sensitize TRPV1. The implication of this finding is that TRPV1 may be more responsible for 
neuropathic pain and neuropathy than previously appreciated following chemotherapy."
"
"
"
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Chapter 1: Chemotherapy-induced neuropathy and TRPV1!
"
Chemotherapy-induced neuropathy is a burgeoning health problem. It is a common 
manifestation of neurotoxicity following treatment for malignancy. One estimate of the 
prevalence states 1/3 of all patients who have chemotherapy experience chemotherapy-
induced neuropathy1. The actual symptoms and clinical signs are dependent on the 
chemotherapeutic agent used, dosing regimen, and previous underlying conditions. The 
distribution of effects can generally be classified by the types of nerves involved, whether 
sensory, motor or autonomic. Where sensory nerves are involved, the condition can be quite 
painful, requiring modification of treatment dose or outright cessation2. For some patients, the 
pain can be severe enough to require cessation of treatment; potentially quite consequential 
from the perspective of cancer treatment outcomes. The mechanisms of this painful 
neuropathy are highly varied, and there is no effective treatment."
"
The modern era has seen dramatic improvements in cancer treatment, extending many lives3. 
The degree to which a cancer therapeutic is effective is wildly dependent on the type of cancer 
and the stage of progression. Consider metastatic, recurring head and neck cancers as an 
example: the median survival if left untreated is estimated at about 3-4 months4, while the 
effect of treatment on median survival appears to add only an additional 2-3 months of time5. 
Testicular cancer, on the other hand, by natural course a severe cancer in young men (90% 5 
year mortality rate), currently has a 5-year cure rate of 80%6. However, with the positive gains 
in treatment, additional problems surface due to adverse effects of these treatments. 
Psychological, digestive, hair/skin-related, fatigue, nausea, fertility-related, sleep-disturbance, 
and taste/oral-changes are just a few types of problems that occur following treatment8-14. The 
prevalence of chemotherapy-induced neuropathy presents a new challenge to understand and 
treat the adverse effects of chemotherapeutics without compromising the anti-tumor efficacy of 
these compounds."
"
There are several major classes of chemotherapeutics that cause chemotherapy-induced 
neuropathy. Antibiotic compounds (e.g. doxorubicin, actinomycin D), platinum based 
compounds (cisplatin, carboplatin, oxaliplatin), alkylating agents (e.g. thiotepa, ifosfamide), 
antimetabolites (e.g. 5-fluoruracil, tegafur), mitotic spindle inhibitors (e.g. vincristine, taxol), 
proteasome inhibitors (bortezomib), topoisomerase I inhibitors (e.g. topotecan, irinotecan), 
and others (e.g. thalidomide, suramin) are many of the different classes of chemotherapeutic 
agents that cause neuropathy6."
"
The actual signs and symptoms can vary dramatically based on the drug of offense. For 
instance, thalidomide frequently causes a large-fiber neuropathy and axonal degeneration, 
bortezomib preferentially targets the small fibers with less axonal degeneration, but more 
direct toxicity on the dorsal root ganglia (DRG) themselves7. Paclitaxel-induced neuropathy 
sometimes comes with the added complication of extreme pruritis, and lenalidomide, a 
recently introduced analog of thalidomide, does not appear to even be neurotoxic6,15,16. For 
many drugs, actual neuropathy-based effects are still unclear; either potential direct autonomic 
effects (e.g. sexual dysfunction, orthostatic hypotension, bradycardia, constipation) are 
attributed to something else, or clinical examinations are not rigorous enough to find the signs 
of neurological deficits7. Neurological symptoms can include numbness, paresthesias, 
allodynia, hyperalgesia, burning, shooting, and/or lightning-like pain through sensory neuron 
involvement, ataxia, muscle weakness, and/or tremors through motor fibers, and constipation, 
impotence, orthostasis, and/or bradycardia via autonomic fiber neuropathy2,7."
"
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Patients receiving these drugs can first begin to experience symptoms within days to months 
following the induction of a treatment regime7. Once the drug is stopped, the symptoms will 
typically abate. Notable exceptions to this being the platinum-based compounds as well as 
thalidomide. In cases from the late 1950’s and early 1960’s when thalidomide was a popular 
nocturnal sedative, thalidomide-induced neuropathy persisted following cessation of treatment 
for three years or more17."
"
Neuropathy is coincident with many conditions, not only chemotherapy treatment. Diabetes 
mellitus is the most common risk factor for neuropathy in general18. Roughly a quarter to a 
third of all persons with diabetes have neuropathy. Based on the estimate of people to have 
diabetes in the year 2030 of 366 million, more than 80 million will live with neuropathy as a 
result of diabetes alone19,20. Other risk factors and causes for neuropathy include nerve 
trauma, nerve entrapment, multiple sclerosis, postherpetic neuralgia, stroke, alcoholism, 
neoplasms, non-alcoholic liver disease, systemic amyloidosis, Sjögren’s syndrome, 
environmental and pharmacological toxins, HIV, hereditary conditions, Lyme disease, 
hemochromatosis, vitamin B6 toxicity, thyroid disfunction, and gammopathies21-23."
"
Presumably, a better understanding of why peripheral neurons are so susceptible to toxicity as 
well as the mechanisms of various neuropathies will lead to increasing treatment success. 
Anatomically, peripheral sensory neurons are very unique. Instead of being protected by the 
blood-brain barrier, these cells are highly susceptible to compounds in the blood and 
extracellular space. A highly fenestrated capillary network surrounds and bathes dorsal root 
ganglia neurons in the contents of the blood24. Additionally, neurons in the periphery are highly 
susceptible to disruptions in the energy supply chain due to their length, which can be over a 
meter. The peripheral terminal of nerve fibers are highly susceptible to neuropathy and also 
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heavily dependent on mitochondrial power. The elevated energy demands of distal epidermal 
nerve fibers could be due to the necessity to constantly break down and remodel in the 
context of tissue (skin) which renews itself every two weeks25."
"
Small-fiber neuropathy can be severely painful. Usually, the onset is length-dependent, 
meaning that the distal tips of the longest nerves are affected first. A typical presentation 
begins as ‘pins and needles’ or parasthesias in the toes and then later the hands. The next 
longest sensory neurons are the intercostal nerves innervating the sternum, the third likeliest 
place for length-dependent pain. But, the pain can begin in less canonical locations as well22. 
Eventually, this develops into a ‘burning’, or ‘lightning-like’ dysesthetic pain and then perhaps 
severe numbness26,27. The occurrence of small-fiber neuropathy does not preclude 
involvement with the larger fibers (motor or sensory). Interestingly, 25% or more of the time, 
the actual cause or underlying risk factor of a neuropathy may be completely unknown28, 
indicating an opportunity to discover exceptional and specific causal mechanisms."
"
Do agents or conditions that lead to neuropathy cause a gain-of-function in a similar manner 
as has been demonstrated with heritable mutations? There are several ion channels that are 
common on peripheral small-fibers that could be modified to cause pain or perhaps 
neuropathy when induced by chemotherapy. TRPA1, NaV1.7, and NaV1.8 have been shown to 
have a role in pain production in models of diabetic neuropathy via activation and modulation 
by methylglyoxal 29-31. Evidence has accumulated for the role of TRPA1 and sodium channels 
in instances of oxaliplatin- and bortezomib-induced cold allodynia32-34. Paclitaxel-induced 
mechanical allodynia is partially blocked by the TRPA1 antagonist, HC-030031 and partially 
blocked by the TRPV4 antagonist, HC-067047, suggesting that both ion channels play a role 
in the painful phenotype following paclitaxel therapy35. "
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"
These studies demonstrate the importance of ion channel function in the context of 
neurotoxicity. Ion channels play a key role in sensory transduction including in the detection of 
noxious stimuli such as extreme heat, cold, or mechanical insults. The TRP (Transient 
Receptor Potential) channels include a diverse array of sensation-capable structures. They 
play roles in vision, smell, hearing, touch, and pain36,37. The TRP vanilloid type 1 (TRPV1) is 
widespread among sensory neurons, is a non-selective cation channel that responds to heat, 
protons, capsaicin (the pungent ingredient of chili peppers), and other substances38. TRPV2, 
TRPV3, and TRPV4 also play a role in thermal sensation. TRPA1, which comes from the 
ankyrin transmembrane protein related group of channels (TRPAs) has a critical for 
chemosensation in nociceptors. It responds to a variety of pungent compounds such as 
mustard oil and wasabi39. TRPM8 (melastatin related TRP) responds to noxious cold40. Other 
channels are important as well for the transmittance of sensory signals such as voltage-gated 
sodium channels, NaV1.7 and NaV1.8, mentioned previously. "
"
As one of the main complaints of small-fiber neuropathy is pain, it is relevant to look at these 
particular channels in the context of pain, both chemotherapy-related and otherwise. The in 
vitro function of naturally occurring mutated versions of NaV1.7, for instance, correlates with 
several atypical conditions and the levels of pain experienced. Nonsense mutations within this 
gene cause a complete insensitivity to pain41-43, while gain-of-function mutations result in 
conditions marked by spontaneous, extreme pain44. Examining the mutated versions of these 
channels in a heterologous expression system showed characteristics diagnostic of 
hypersensitivity, either impaired inactivation of sodium currents, increased resurgent currents, 
or the neurons had depolarized resting potentials, rendering them hyperexcitable28."
"
 9
Pain is not the only thing connected to malfunctioning ion channels. In the case of Nav1.7 and 
Nav1.8, it appears as though there is some overall role of the channel in the development of 
neuropathy itself, perhaps by depolarizing resting membrane potentials or a generally 
incrased excitability of sodium currents28,45,46. Blocking these channels with tetrodotoxin 
confers neuroprotective effects, possibly by limiting their activity and preventing subsequent 
apoptotic pathways from activating47."
"
Ion channel disturbances have been directly connected with neuropathy. Recent work has 
connected cases of idiopathic small-fiber neuropathy with malfunctioning Nav1.7 and Nav1.8 
channels. Previously it was shown that NaV1.7 gain-of-function mutations result in painful 
conditions known as paroxysmal extreme pain disorder and inherited erythromelalgia48. The 
function of these sodium channels alone predicted hypo- or hyper-sensitivity to pain. 
Depolarized resting membrane potentials and general hyperexcitability of sodium currents 
could initiate apoptotic pathways if additional metabolic demand is added on top, and again, 
using TTX (tetrodotoxin) to block sodium channels conferred protection on these cells47."
"
Another channel that was mentioned previously and extensively-studied in the context of heat 
hypersensitivity is TRPV1. It has not, however, been so explored in the context of 
chemotherapy-induced neuropathy. TRPV1 is expressed in a large proportion of the 
peptidergic small-diameter c-fibers, with cell bodies located in the dorsal root and trigeminal 
ganglia of the peripheral nervous system and fiber endings spread throughout the skin, joints, 
muscles and visceral tissue49. TRPV1 is also located centrally in the thalamus, locus 
coeruleus, periaqueductal grey, and cortex51-54. As was mentioned previously, TRPV1 is 
responsive to noxious heat, pH changes, and various endogenous and exogenous ligands. 
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Due to TRPV1’s ability to detect a variety of noxious stimulants, it is referred to as a ‘gateway’ 
to the pain pathway or as a coincidence detector55,56."
"
Additional evidence of the importance of TRPV1 in painful conditions is the demonstrated 
increase of TRPV1 protein expression following experimental inflammatory conditions57 as 
well as the increased expression in the case of painful clinical conditions such as esophageal 
inflammation, irritable bowel syndrome or interstitial cystitis58,59. Moreover, knocking out or 
knocking down TRPV1 partially protects animals from mechanical, thermal and chemical 
pain60-65. As well, blocking TRPV1 pharmacologically with antagonists results in a similar 
reduction of pain-like behaviors in animal models of pain66-68. "
"
The implication of TRPV1 in the development of burning pain following chemotherapeutic 
treatment is intellectually satisfying, but its role is still largely unknown in the context of 
chemotherapy-induced neuropathy. TRPV1 has been shown to be necessary for heat 
hyperalgesia for a cisplatin-induced in vivo neuropathy animal model69, while an earlier study 
showed that TRPV1 knockout animals were not less, but more susceptible to a cisplatin-
induced model of thermal and mechanical hyperalgesia60. In a cisplatin-induced hearing loss 
model, knocking down TRPV1 did confer some benefit to the animal’s ability to hear, 
suggesting that TRPV1 malfunction contributes to neurotoxicity70. Other cases indicate a 
sensitization of TRPV1 function following chemotherapy such as increased CGRP release 
following capsaicin-stimulation of neurons in culture and increased expression levels along 
with paclitaxel-induced thermal hyperalgesia reversed by TRPV1 antagonists71,72. The 
mechanical-, cold- and heat hyperalgesia following paclitaxel treatment are mediated via mast 
cell-based sensitization of TRPV1 among other TRP channels V4 and A173.!
"
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If TRPV1 plays a key role in the development of pain and/or neuropathy following 
chemotherapy, then a diverse array of modulators exists already as treatment options74. While 
TRPV1 antagonists have not been particularly effective analgesics75, there have been 
promising advances in development that are still playing out76. An additional, more tangential 
strategy for dampening the role of TRPV1 in pain is by modifying or reducing its capacity for 
sensitization. Interfering with an important TRPV1 scaffolding protein diminishes pain 
behaviors in a formalin-injection model of spontaneous pain77. The scaffolding protein 
involved, AKAP79/150, was previously shown to be a convergent pathway of sensitization for 
PKA, PKC, and PIP2 based modulation of TRPV178-81."
"
There is no single pathway for pain processing; in the brain or in the periphery. It is important 
to note, some of the most painful conditions may actually be independent of ‘normal’ 
nociceptors, instead coming through the large, myelinated and fast Aβ fibers (trigeminal 
neuralgia, for instance82). After nociceptors synapse onto neurons within the central nervous 
system, neurons traversing the spinothalamic and spinoreticulothalamic tracts pass along pain 
signal to the thalamus and brainstem83. There are many different regions involved in the 
processing of pain, all receiving parallel inputs84,85. In similar fashion, there are multiple 
pathways to neuropathy following chemotherapy. And likely, of necessity, many pathways to 
treatment, some effective under some conditions, and some in others."
"
Conclusion!
Pain and nociception typically serve a vital and useful purpose. Aberrant nociceptive feedback 
in the case of neuropathic pain can be severely debilitating, as is the case with peripheral 
small-fiber painful neuropathy due to chemotherapy. The increasing incidence of 
chemotherapy-induced neuropathy calls for a deeper understanding of the mechanisms of 
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pathology. Increasing our understanding of the roles of ion channels on neuronal function in 
health and disease is an important piece in grasping the big picture of neuropathy. "
"
Chemotherapeutic-induced pathology represents a relatively recent and shifting set of 
scientific problems. A clearer understanding of the pathology and progression of symptoms 
following chemotherapy could aid in the development of suitable countermeasures for 
patients. Additional awareness of chemotherapy-induced neuropathy during the development 
could help find drugs that have similar cancer treatment profiles as drugs already in use, but 
without the adverse effects, although it is difficult to imagine. Fortunately, there appears to be 
no limit to the options ahead of us86,87. Neuropathic pain is one example of the dreadful impact 
of chemotherapy treatment. It is still not well understood how the particular chemotherapeutics 
lead to the development of pain or neuropathy. Mitigating the development or blocking the 
pain would have a profound impact on quality of life in cancer patients. In a respect, as pain 
can be dose-limiting, properly dealing with it may have an impact on survival-based outcomes. 
TRPV1 function is potentially an important part of the development of neuropathy following 
treatment by certain chemotherapeutics."
"
"
"
"""""""""""
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Chapter 2: Kinetic high-throughput imaging of primary sensory neurons* !1""
Abstract!""
We describe a dynamic high-throughput paradigm to identify small molecules and peptides 
that target murine primary sensory neurons. The method allows for the study of protein targets 
in their native cells, improving on current methods focused on heterologous expression 
systems. These approaches are flexible as a primary screen, or they can be used to study 
additional functional characteristics of neurons, while profoundly reducing the time and effort 
spent in conducting traditional microscopy-based experiments."
"
Introduction!
There has been an explosion of various “omics” datasets that presents a complex network of 
protein and pathway interactions in systems neurobiology1. To explore this complexity, there is 
a pressing need to study receptor-ligand interactions in concert with their pathways in an 
efficient and high-throughput fashion. In the past decade, the emergence of high-throughput 
screening (HTS) technologies that utilize sophisticated robots and process ~100,000 reactions 
a day has had a profound impact on basic biology and drug discovery2. However, these 
endeavors have been limited to heterologous expression systems, commonly in HEK or CHO 
cells for at least two reasons: 1) these cell lines are easily scalable to an experiment requiring 
large amounts of cells, and 2) a specific target protein can be expressed in these cells to study 
its effects individually. However, such an approach requires that the experimenter knows the 
target a priori and the artificial environment does not lead to spurious results. By using primary 
neurons, there is an additional world of potential targets, that can lead to the study of 
* Work attribution - This work was done in close collaboration with Ajay Yekkirala. We jointly performed 
the dissections and optimization of the imaging technology together. Takao Omura and Michio Painter 
provided sciatic nerve crush pre-conditioned animals and neurons for measuring neurite outgrowth.
physiologically relevant pathways and signal cascades. An additional advantage of using 
primary neurons is the existence of a native ‘supporting cast’ of scaffolds, signaling molecules, 
etc., ensuring the most appropriate post-translational state (Table 2.1). Hence, a method to 
study receptors and pathways in primary cultured neurons is highly desirable. To address this 
critical issue, we describe a dynamic high-throughput paradigm that can be applied to primary 
sensory neurons; we show that it is feasible, robust, versatile, and efficient. "
"
Methods!
Dissection and culture!
Male adult C57Bl/6 mice were purchased from Jackson Laboratories and housed in the animal 
facilities of Children’s Hospital Boston on a 12 hour alternating light-dark cycle. Animals for 
imaging were dissected after 7 weeks of age. After CO2 asphyxiation and cervical 
translocation, and following spinal laminectomy, the left and right dorsal root ganglia (DRG) 
from the whole spine were removed and placed in 4ºC Hanks buffered saline solution without 
calcium and magnesium (HBSS, Life Technologies). After the DRG were collected and spun 
down for 3 minutes at 1000 rpm (150 g), they were placed in a collagenase/dispase solution (3 
mg/mL dispase II and 1 mg/mL collagenase A, Roche Applied Science) and allowed to 
incubate at 37°C for 90 minutes. After incubation the cells were washed in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Life Technologies), fortified with 4.5 g/L D-glucose, L-
glutamine, 110 mg/L sodium pyruvate, 10% fetal bovine serum (Life Technologies), penicillin 
(500 U/mL, cellgro), and streptomycin (500 µg/mL, cellgro). DNAse (125 U/mL, Sigma) was 
then added and the solution was triturated using successively smaller caliber flame-polished 
pasteur pipettes. This solution was gently layered onto a bovine serum albumin gradient (10% 
albumin from bovine serum, Sigma in PBS, Life Technologies) and spun at 150 g for 12 
minutes. After removal of the supernatant, the cells were washed again in DMEM, suspended 
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in neurobasal medium (Life Technologies) supplemented with L-glutamine (20 mM, Life 
Technologies), B-27 supplement (Life Technologies), penicillin (500 U/mL, cellgro), and 
streptomycin (500 µg/mL, cellgro) and then plated onto laminin-treated (1 mg/mL, Sigma) 15 
mm glass-bottom dishes (MatTek Corporation), and then placed in an incubator at 37°C (5% 
CO2) overnight. All imaging was performed one day post-dissection and culture."
"
Calcium Imaging!
DRG neurons were imaged on a Nikon Ti Eclipse inverted microscope. Fura-2, AM (Life 
Technologies) was loaded into the neurons for 30 minutes (room temperature, 4 µg/mL). After 
washing with standard extracellular solution (Boston BioProducts), the cells were imaged 
using a QImaging EXi Aqua cooled camera and data was collected and analyzed using NIS 
Elements software (AR 3.10). Neurons were selectively exposed to various solutions via a 
gravity-assisted perfusion system. Responses were included if they were 20% greater than 
baseline."
"
Statistical parameters for assay development!
The Z-factor is a statistical measure to determine the suitability of a high-throughput assay for 
finding ‘hits’. It incorporates the variability of both positive and negative controls to determine 
how ‘good’ an assay is. We used the Z-factor merely to determine an optimal number of cells 
to use for this assay. It is calculated with the mean values and standard deviations from 
positive (   and   ) and negative (   and   ) controls. Developed by Zhang and 
colleagues14, it uses the following formula:"
" "   ."
µp σ p µn σ n
Z = 1− (3σ p + 3σ n )| µp − µn |
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We used the Z-factor to gauge the best number of cells to use per well as a way to optimize 
the assay for direct activation using the best case scenario KCl as an indication of response. "
"
Calcium flux protocol – Hamamatsu!
DRG neurons were dissected from adult (~8 week old) C57Bl/6 mice as described above. 
After dissociation, cells were seeded into 384 well plates coated with laminin (Greiner, Inc.) at 
2000 cells/well in a volume of 25 mL/well of neurobasal medium and incubated overnight at 
37°C and 5% CO2.  The plates were assayed for calcium flux using the FLIPR calcium-5 kit 
(Molecular devices) in an FDSS-7000Ex apparatus (Hamamatsu) with increasing 
concentrations of the test ligands. The response was measured in relative fluorescence units 
(RFU) and the ratio of change in well fluorescence (Ratiomax - Ratiomin)was computed over 
time. The data was then analyzed as percent of Basal RFU = (Ratiomax-Ratiomin)treatment/
(Ratiomax-Ratiomin)control x 100 and plotted using Prism 4.0 analysis software (GraphPad, Inc.). 
For sensitization assays, the potentiation of CAP 100 nM response was computed as % 
potentiation over control = ((Ratiomax)treatment - (Ratiomax)control)/(Ratiomax)control x 100 and 
presented in Prism 4.0. "
"
HT neurite outgrowth assay:!
DRG neurons were dissected from naïve and injured Thy1-YFP mice (~8 weeks old) 
expressing the YFP reporter as described above. After dissociation, cells were seeded into 
384 well plates coated with laminin (Greiner, Inc.) at 2000 cells/well in neurobasal media (50 
mL/well) and incubated overnight at 37°C and 5% CO2. The plates were then assayed for YFP 
reporter expression (Ex/Em = 488 nm/509 nm) in an FDSS-7000Ex apparatus (Hamamatsu) 
after adding 5mL of trypan blue to quench any well autofluorescence. The response was 
measured as Relative Fluorescence Units (RFU) and plotted using Prism 4.0 analysis 
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software (GraphPad, Inc.)."
"
Sciatic nerve crush!
Surgeries for peripheral injury were performed as published previously3. The sciatic nerve was 
clamped with a smooth forceps (5/45, Fine Scientific Tools) for 30s at the level of the proximal 
thigh, to inflict injury. A 10-0 nylon suture was knotted to the epineurium to mark the crush site. 
All procedures were performed under anesthesia. "
"
Efficiency Model!
We used three main components to estimate the amount of time per mouse. They are: time 
for dissection (Td), time for culture (Tc), and time for imaging (Ti). Each component occupies its 
own amount of time dependent on the method of imaging employed. In the high-speed format, 
equation (1) can approximate the amount of time (hours) by each set of mouse DRG neurons 
included in the experiment:"
"
"   " (1)"
If m = the number of mice used for dissections, Td = , Tc =  and "
Ti = ."
Comparing this model with traditional microscopy-based experiments, the main differences 
are in the Ti parameter. Assuming t(m) is the total time required as a function of number of 
mice, the model is shown by the following formula (2):"
t = m2 +
1
2
m
3
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"
  " " " " (2)"
The greatest difference between these two models is the necessity of imaging experiments in 
series in the traditional calcium imaging setup, while such experiments can be done in parallel 
in the high-throughput method. However, there are additional time-based advantages aside 
from this, including the increased efficiency of dissecting and culturing of DRG neurons from 
several mice in one session. "
"
Results!
The first step towards establishing this method required insight into the practical issue of 
numerical feasibility. For HTS experiments with cultured cells in 384-well plates, cells are 
typically seeded at a density of around 20,000 cells/ well. However, given that we typically 
t = m + 3m + 12
26m
3
⎛
⎝⎜
⎞
⎠⎟ +
1
4 (26m)
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Table 2.1 - Comparison between mammalian cell line and primary sensory neurons.
extract ~50,000 DRG neurons per adult mouse, we set out to determine the least possible cell 
density that would provide robust and reproducible calcium ion fluxes. Utilizing the FLIPR 
calcium 5 kit (Molecular Devices) we seeded freshly-dissociated DRG neurons in increasing 
density, ranging from 500 cells to 5000 cells/well in a black, clear-bottom 384 well plate 
(Greiner) treated with laminin (1 mg/mL) (Sigma). After 24 hours, the cells were tested with 40 
mM KCl to induce calcium flux in all neurons and 1 µM capsaicin, a transient-receptor 
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Figure 2.1 - Calcium flux method was established for DRG neurons in a 384-well format. (A) 
Cells were seeded in a range of 0 to 6000 cells/well in 384-well black, clear-bottom plates and 
tested for calcium flux with KCl and capsaicin. 2000 neurons/well provided robust calcium flux 
responses for both KCl and capsaicin and became our default cell density for the procedure. (B) 
Capsaicin concentration-response curve was generated for DRG neurons with an EC50 of 121 
nM. (C) Small scale screening experiments were performed with a few peptide ligands and 
small molecules to identify direct activators of sensory neurons. (D) Functional sensitization of 
TRPV1 channels was interrogated with a 10 minute incubation of known potentiators preceding 
application of capsaicin (100 nM). Several ligands produced strong potentiation of capsaicin-
induced calcium flux. All experiments were performed with three biological replications. 
Potentiation from control indicates the change (%) of overall signal. One-way ANOVA was 
performed followed by Dunnett’s post-hoc test to evaluate the significance of the results (** 
denotes p<0.001, * denotes p<0.05).
)LJ
potential vanilloid-1 (TRPV1) receptor agonist4, in an FDSS 7000ex apparatus (Hamamatsu). 
Both KCl and capsaicin produced robust calcium flux and clear, cell density-dependent 
responses (Figure 2.1a). We show that 2000 cells is sufficient to achieve a robust Z-score 
with direct activation using 40 mM KCl14 (Supplementary Figure 2.1 and Supplementary 
Figure 2.2), increasing our confidence that 2000 cells per well was an appropriate choice for 
cell density in the case of direct activation. Importantly, since we were able to use as few as 
2000 neurons/well we were convinced that, indeed, using primary neurons in an HTS-based 
experimental setup is quite feasible.!
""
To better understand the optical sensitivity of the cells in individual wells of a 384-well plate, 
we measured the coverage area of the cultured neurons and response percentage of 
capsaicin (1 µM), and KCl (40 mM) by using an inverted microscope (Nikon Ti Eclipse) 
(Figure 2.2a-c). Roughly half of all neurons were activated by capsaicin (42 ± 5.3%), 
corresponding to ~6% of the surface area of the well (Figure 2.2d). To further see how the 
system handles a dynamic range of calcium fluxes, we generated a concentration response 
curve (CRC) for capsaicin. After four independent biological replicate experiments we 
calculated an EC50 of 127.2 nM (Figure 2.1b), which is comparable to the EC50 described for 
capsaicin in cultured cells stably expressing TRPV1 (99-900 nM; ref. 4-6) and in cultured 
murine neurons (200 nM; ref. 7)."
"
The fact that we are using primary neurons allows for testing receptors and pathways in their 
native environment - a major advantage when compared with artificial expression in 
heterologous cell lines. We explored this versatility by assaying for neuronal direct activation 
and TRPV1 sensitization, as both phenomena have been shown to play important roles in 
nociception. We observed that several ligands produced visible calcium fluxes upon addition 
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(Figure 2.1c). Moreover, known sensitizers of TRPV1 such as forskolin (100 µM)8, IL-1β (10 
ng/mL), GDNF (0.2 ng/mL), and prostaglandin E2 (PGE2) (3 µM)9 produced statistically 
significant sensitization of a low capsaicin (100 nM) response after a 10 minute incubation 
period (Figure 2.1d). 
"
Aside from direct activation studies and sensitization, DRG neurons are also frequently 
assayed for neurite outgrowth in the context of peripheral nerve regeneration and 
neuropathies10. We wanted to gauge if we could rapidly track changes in neurite-outgrowth of 
DRG neurons in a high-throughput format. A pre-conditioning crush injury to the sciatic nerve 
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Figure 2.2 - Characteristics of plate coverage and activation. (A) Brightfield image of dorsal root 
ganglia cells plated at 2000 cells per well. (B) Dorsal root ganglia cells plated and loaded with 
FLIPR calcium-5 dye (Molecular Devices) viewed by fluorescence at same magnification as in 
(A). (C) % coverage of well area as calculated using ImageJ software. (D) Complete response 
percentages among DRG cells for TRPA1 (AITC), TRPV1 (CAP = capsaicin) and KCl (all 
responsive neurons). (E) representative traces of individual neurons responding to capsaicin (3 
µM).
6XSSOHPHQWDO)LJ6
results in increased neurite outgrowth in culture11. This phenomenon can be readily observed 
in vitro after plating DRG neurons isolated from L3-L5 ganglia of yellow fluorescent protein 
(YFP) -reporter mice (Thy1-YFP)12 with and without sciatic nerve injury. The neurons after 
preconditioning injury show a marked enhancement in neurite outgrowth, presumably leading 
to increased well fluorescence (Figure 2.3a, b). We again found a cell density of 2000 cells/
well to be optimal for examination of both enhancers and inhibitors of neurite outgrowth 
(Figure 2.3c). At this cell density we observe ~90% increase in well fluorescence from 
neurons after pre-conditioning injury when compared with neurons from naive mice (Figure 
2.3d). In addition to this experiment showing increased neuronal growth, we were able to 
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Figure 2.3 - High-throughput neurite outgrowth assay. Purified DRG neurons from a reporter 
line that labels mechanoreceptors (Thy1-YFP) were seeded into 384-well black clear-bottom 
plates (Greiner Inc.) before (A, D) and 5 days after a ‘preconditioning’ sciatic nerve injury (B, D). 
Eighteen hours later, total well fluorescence was quantified in an FDSS-7000 apparatus 
(Hamamatsu) and preconditioned neurons showed >90% increase in fluorescence when 
compared with naïve neurons. Treatment with cisplatin (1 µM), a chemotherapeutic agent, 
produced ~70% reduction in well fluorescence that correlates well with the loss of neurites; 
asterisk, P <0.001 (ANOVA followed by Dunnett’s test). (C) We quantified the fluorescence 
intensity vs cell number to identify the number of neurons required for robust response. "
)LJ
reproduce cisplatin-induced reduction of neurite outgrowth (Figure 2.3d) as an example of 
chemotherapeutic-induced neuropathy13. "
"
The hallmark of this method is the fact that it is a directed approach to study a complex 
cellular subtype that are sensory neurons in an unbiased, high-throughput format. In 
generating a concentration response curve for capsaicin, we estimate that we saved over 16 
hours of experimentation time. Based on our model of workflow and output, for simple 
experiments such as direct activation, sensitization or the generation of concentration 
response curves, this system is extremely time economical (for more complete details on 
model, see methods section). Importantly, there is little difference in the number of mice that 
need to be dissected to screen a given number of compounds, but the similarities end there as 
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Chart 2.1 - Comparative analysis between traditional and high-throughput imaging methods. 
The proposed method provides ~ 6-8-fold advantage in total time spent to study similar number 
of compounds without the need for additional dissections.
&KDUW high speed
high 
speed
we can incubate all the wells in a plate with dye, and read the entire plate at the same time 
(Chart 2.1). "
"
Due to the fact that the output signal in this system is an integrated and simplified trace for a 
whole population of heterogenous neurons, it is important to note the lack of neuron-specific 
information. For instance, we are unable to identify the specific percentage or populations 
(such as small, medium or large) of neurons that are contributing to the measured 
fluorescence output parameters. An important consideration particularly when DRG neurons 
are used, is that any non-neuronal cell in culture with DRG neurons can contribute to calcium 
signals indiscriminately. We propose that these methods be utilized as a primary screen, 
taking advantage of the speed and volume of compounds that can be tested with relative ease 
in a primary sensory neuron. The best hits and controls should then be tested by utilizing 
conventional microscopy techniques, thus serving to validate the data from the unbiased high-
throughput method."
"
Conclusions!
Primary sensory neurons provide an intact neuronal environment, independent of 
heterologous expression, for unbiased screening approaches. Signaling pathways, scaffold 
proteins, and other necessary molecules are in place to provide proper support for 
interrogating cellular function, allowing a platform for elemental and unbiased discovery. 
Indeed, DRG neurons have been used extensively for neurobiological studies via traditional 
biochemical, microscope-based imaging, and electrophysiological techniques. Given that 
sensory neurons are of primary importance in heat, cold, pain and itch sensing, to name a few, 
this high-throughput method will serve to identify biologically relevant endogenous and 
exogenous ligands that modulate nociception and sensory perception, adding an additional 
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and important tool to the arsenal of analgesic drug discovery. Generating concentration 
response curves, assaying direct activation and sensitization, as well as neurite growth assays 
(even dynamic growth assays where the chamber is incubated) are all possible in primary 
sensory neurons in an efficient and large-scale manner. The additional context of an intact 
primary cell also makes this paradigm adaptable for interrogating the intracellular biology of 
any assay that can be performed, either by blocking specific pathways prior to functional 
analysis, and/or antagonizing receptor function via pharmacological means in a high-
throughput fashion. Moreover, we suggest that our approaches should be utilized for 
their speed and relative ease to set up, as a primary screen, and then complemented 
with traditional microscope-based imaging, biochemical, and electrophysiological 
methods of interrogation. It is conceivable that such a tandem approach has 
tremendous potential to make quick and efficient neurobiological discoveries in the 
near future. "
"""""""" """
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Chapter 3: Proteasome inhibition sensitizes TRPV1 in DRG neurons* !2""
ABSTRACT"
TRPV1 is a ligand-gated ion channel primarily expressed in small fiber sensory neurons and is 
important for the transmission of pain sensation in the nociceptors. TRPV1 is activated in 
response to noxious heat (~42 ℃) and is sensitized through various internal signaling 
mechanisms. The sensitization of this channel has never been studied in a high-throughput 
un-biased approach. We developed a method using primary sensory mouse neurons in a 
high-throughput apparatus to examine the sensitization of TRPV1. We applied this method to 
discover TRPV1 sensitization characteristics following many different compounds, including 
bortezomib, a proteasome inhibitor used to treat multiple myeloma. This compound frequently 
causes painful neuropathy in patients. The mechanism of this is unknown, even as it is a 
dose-limiting effect of this effective cancer treatment. As demonstrated further via traditional 
cell-focused calcium-imaging experiments, bortezomib sensitizes TRPV1 in vitro. These 
results highlight a hypothetical mechanism of the painful aspects of bortezomib-induced 
polyneuropathy that is TRPV1-sensitization dependent. More fundamentally, TRPV1 
hyperfunction could drive a calcium-induced toxicity leading to the neuropathy itself."
"
INTRODUCTION"
TRPV1 (transient receptor potential vanilloid type 1) is a non-selective cation channel that 
plays a critical role in the sensation of pain. In the peripheral nervous system it is directly 
activated by painful heat (~42 ℃), protons, and the ‘hot’ ingredient in chilis, capsaicin1. 
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* I performed the initial screen of this work jointly with Ajay Yekkirala with the assistance of Navid 
Soltani. I performed all rig-based calcium imaging and several additional FDSS 7000EX follow-up 
experiments, sometimes with the assistance of Ajay Yekkirala or Octavio Viramontes. I also performed 
the qPCR experiments and worked in collaboration with Nick Andrews, Alban Latremoliere, and 
Catherine Ward, who performed all the behavioral assays.
Functional TRPV1 is a tetrameric ion channel with 6 transmembrane domains for each 
subunit, plus one pore loop. TRP channels are a group of more than seven subfamilies of 28 
different subunit proteins2. TRPA, TRPC, TRPL, TRPM, TRPN, TRPP, and TRPV are the 
various families belonging to the TRP channel group. The first TRP channel was discovered to 
be important in visual transduction in flies3. The particular functions of all members of the TRP 
family are highly varied, but some of the common elements include six transmembrane 
domains, the formation of tetramers, and all channels are cation-selective, although the 
balance between different cations varies3. Additional details such as ankyrin repeats and the 
‘TRP’ domain are common elements but vary in details between channels2-7. "
"
TRPV1 is a remarkable protein for the variety of ways that it can be activated from outside the 
cell (heat, capsaicin and other compounds, acid), as well, TRPV1 is sensitive to modulation 
via internal phosphorylation events. PKC, PKA, PI3K, calcineurin, PDK1, and Cdk5 have all 
been shown to phosphorylate TRPV1 at specific serine and threonine residues8, leading to 
attenuated responses9-14. Via sensitization, TRPV1 can become more responsive to noxious 
stimuli (hyperalgesia) or responsive to agonists that normally would not cause pain 
(hypoalgesia). Some of these agonists may be internal, such as heat or some known 
activators such as endogenous compounds: including the endocannabinoid, anandamide15, 
lipoxygenase products 12-(S)-HPETE, 15-(S)-HPETE, 5-(S)-HETE, 15-(S)-HETE, leukotriene 
B416, or DAG17. TRPV1 activity serves as an archetype for peripheral hypersensitivity; it 
becomes more responsive due to phosphorylation-based sensitization following NGF, GDNF, 
IL-1β, PGE2 and bradykinin18-22. TRPV1 is sensitized in cell-based assays by various growth 
factors, internal signal arachidonic acid metabolites, lipids and other peptides. The 
sensitization of TRPV1 mirrors what actually happens when these same compounds are 
injected into the skin of human or animal test subjects; it causes pain hypersensitivity23-26."
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"
Studying TRPV1 sensitization in vitro in the traditional research paradigm has relied on an 
important cellular phenomenon of TRPV1: the development of short-term desensitization. 
When TRPV1 is exposed to capsaicin or other agonists it becomes desensitized to further 
activation by capsaicin in the short-term (minutes)27. This process is largely calcium-
dependent, relying in part on the protein phosphatase, calcineurin, and calcium-binding 
protein calmodulin to inhibit TRPV1 activation during a latency phase4,28-30. Reverting this 
process is considered to be sensitization. Typically, blocking desensitization in vitro is 
accomplished by modifying the phosphorylation status of TRPV18. While many compounds 
have been discovered that modulate the desensitization of TRPV1, it is not clear how these 
same compounds effect the sensitization of TRPV1 in the absence of desensitization. It is 
difficult to test multiple varied conditions at once and challenging to examine TRPV1 
responsiveness following a lengthy sensitization period (hour+). To address some of these 
issues, we undertook the task of developing a high-throughput sensitization model of TRPV1 
using primary sensory neurons taken from the dorsal root ganglia (DRG). Rather than relying 
on desensitization, this model would measure the sensitization of TRPV1 directly following 
exposure to a variety of compounds. Instead of comparing measurements from individual 
neuronal cells (highly heterogenous), we measured from a population of neurons (2000+ 
neurons), thus smoothing over any local heterogeneity issues. We utilized a 480-compound 
library of well-annotated bioactive molecules to look for TRPV1 sensitization following 
simultaneous exposure to a diverse set of molecules (ScreenWell® ICCB Known Bioactives 
Library). "
"
We dissected and cultured primary sensory neurons from mice and assayed them in a 384-
well format for sensitization of TRPV1 following 24 hour exposure to the 480 compounds in 
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the BioMol library. This system allows us to test several hundred compounds for TRPV1 
sensitization; a phenotypic outcome, in an unbiased manner. By being able to directly assess 
TRPV1 sensitization independent of desensitization and using native neurons with native 
amounts of TRPV1 expression with signaling pathways and protein scaffolding intact, we can 
exploit an opportunity to uncover clinically relevant sensitizers of TRPV1. To our knowledge it 
is the first attempt to test so broadly for TRPV1 sensitization."
"
METHODS"
Dissection and culture of DRG neurons!
Male adult C57Bl/6 mice were purchased from Jackson Laboratories and housed in the animal 
facilities of Children’s Hospital Boston on a 12 hour alternating light-dark cycle. Animals for 
imaging were dissected after 7 weeks of age similarly to the procedures outlined previously31. 
After CO2 asphyxiation and cervical translocation, and following spinal laminectomy, the left 
and right dorsal root ganglia (DRG) from the whole spine were removed and placed in 4 ºC 
Hanks buffered saline solution (HBSS, Life Technologies). After the DRG were collected and 
spun down for 5 minutes at 1000 rpm (150 g), they were placed in a collagenase/dispase 
solution (3 mg/mL dispase II and 1 mg/mL collagenase A, Roche Applied Science) and 
allowed to incubate at 37°C for 90 minutes. After incubation the cells were washed in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies), fortified with 4.5 g/L D-
glucose, L-glutamine, 110 mg/L sodium pyruvate, 10% fetal bovine serum (Life Technologies), 
penicillin (500 U/mL, cellgro), and streptomycin (500 µg/mL, cellgro). DNAse (125 U/mL, 
Sigma) was then added and the solution was triturated using successively smaller caliber 
flame-polished pasteur pipettes. This solution was gently layered onto a bovine serum albumin 
gradient (10% albumin from bovine serum, Sigma in PBS, Life Technologies) and spun at 150 
g for 12 minutes. After removal of the supernatant, the cells were washed again in DMEM, 
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suspended in neurobasal medium (Life Technologies) supplemented with L-glutamine (20 mM, 
Life Technologies), B-27 supplement (Life Technologies), penicillin (500 U/mL, cellgro), and 
streptomycin (500 µg/mL, cellgro) and then plated onto PDL and laminin-treated (1 mg/mL, 
Sigma) 15 mm glass-bottom dishes (MatTek Corporation), or placed into laminin-treated 384-
well optical plates (Greiner) and then placed in an incubator at 37 °C (5% CO2) overnight. 
Plating density in the 15 mm optical plates was between 150-250 cells/µL, while in the 384-
well optical plates was 80-120 cells/µL. "
"
FDSS7000EX - 384-well imaging!
Cells were plated at 2000 cells/25 µL/well in neurobasal medium (Life Technologies) in 
laminin-coated (1 mg/mL, Sigma) borosilicate glass-bottomed and black polystyrene cased 
384-well plates (Sensoplate, Greiner). Within 3 hours of plating the cells, a 2.5 µL drop of the 
384-well screening plate (ICCB, Screen-Well® Bioactive Molecules, plates 3402 and 3403) 
was added using the FDSS7000EX (Hamamatsu). After overnight incubation at 37 °C with 5% 
CO2, the wells were then loaded with 20 µL of FLIPR 5 calcium dye (Molecular Devices). We 
preloaded all ligand solutions at 5x concentrations in individual v-shaped conical-bottomed 
384-well polypropylene plates (Greiner) when we custom prepared the ligand plates. Library-
based ligand plates were purchased from the Institute of Chemistry and Cell Biology (ICCB, 
Harvard Medical School) screening facility. Solutions were added following mechanical 
trituration from stages 1 and 2 at 10 and 12 µL, and 10 µL/s and 12 µL/s respectively. 
Solutions were added at a height of 2.4mm from the bottom of the assay plate. Primarily, the 
drop period with the following 20-30 seconds was sampled at 2.5 Hz, otherwise samples were 
taken at .33 Hz. The camera used is a digital CCD camera C9100-13 (Hamamatsu) with an 
exposure time of 200 ms with 2x2 binning. The light source is a LightningCure™ LC8 
(Hamamatsu) bulb that was passed through a 472 nm excitation filter and collected at 540 nm.  
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Solutions of capsaicin (end concentration of 100nM - drop of 10 µL) and KCl (end 
concentration 5mM for sub-maximal and 40mM for maximal with drop of 12 µL) or HBSS 
(vehicle for all solutions) were added at various times. The responses were measured as 
relative fluorescence units, initially captured using FDSS7000EX/uCell software and analyzed 
on Excel (Microsoft) for area under the curve (AUC), plotted on Prism analysis and 
visualization software (Graphpad). Data points are collected as relative fluorescence and then 
are modified to ratio values post-collection. The first frame of each well equals the baseline, 
and all following responses are calculated as a ratio of the initial fluorescence (Ratio). Percent 
change of response was calculated as: "
" "    (1)"
Where    is the fluorescence signal of all accumulated signal (AUC) of the treated well, and 
   is the AUC fluorescence ratio signal of the untreated well, but still activated with capsaicin. 
In some experiments additional controls were used to calculate the actual % sensitization or 
desensitization. These required treated controls that, instead of capsaicin agonism following 
treatment were given vehicle control (HBSS). % sensitization is calculated by first subtracting 
the treated negative control (vehicle following treatment) from the treated and challenged wells 
and is referred to as the ΔRatio. The ΔRatio is used as in Formula (1) to calculate % change 
as an actual sensitization or desensitization of response."
"
Compound library!
The ScreenWell™ ICCB Known Bioreactives Library (BioMol) was purchased through the 
Assay Development and Screening Facility Core at Boston Children’s Hospital who worked 
with the Institute of Chemistry and Cell Biology at Harvard Medical School (Boston) to 
Rx − Ry
Ry
Rx
Ry
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formulate the plate. The BioMol library is a 480-compound library of well-annotated chemicals 
with diverse topologies and mechanisms of action. The complete list of compounds can be 
found here: http://iccb.med.harvard.edu/biomol-known-bioactives-2012-list-of-compounds/. 
The daughter library plate was formed by adding a 30 nL pin drop to 300 µL HBSS for a 
10000-fold dilution. This library was kept at 4 ℃ for 2 weeks and used within that time. Many 
of the compounds in the Screen-Well® ICCB Known Bioactives (BioMol) Library activate 
specific signaling pathways and receptors as well-suited experimental compounds in addition 
to including a large proportion of compounds that are used in the clinic. Although this library is 
small by industry-standards, it offers a wide and diverse set of topologies and targets, well 
suited for an experiment in primary sensory neurons32."
"
Calcium Imaging!
DRG neurons were imaged on a Nikon Ti Eclipse inverted microscope. Fura-2, AM (Life 
Technologies) was loaded into the neurons for 30 minutes (room temperature, 4 µg/mL). After 
washing with standard extracellular solution (Boston BioProducts), the cells were imaged 
using a QImaging EXi Aqua cooled camera and data was collected and analyzed using NIS 
Elements software (AR 3.10). Neurons were selectively exposed to various solutions via a 
gravity-assisted perfusion system. Responses were included if they were 20% greater than 
baseline. The perfusion rate of the solutions was 0.6 mL ・min-1 and the pencil tip was 150 µm 
away from the field of view."
"
Statistics!
Comparisons between groups with respective n more than 8 were made using students’ t-test. 
Comparisons of distributions were made using the Kolmogorov-Smirnov test in Stata 
(StataCorp LP). Quantile-quantile plots were derived in Excel (Microsoft) by interpolation."
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"
RNA extraction!
Cells were cultured under standard plating and imaging conditions. After treatment or control, 
the media is removed and 500 µL TRIzol® (Life Technologies) is added and cells are scraped 
off and mixed well, incubating at RT for 5 minutes before adding to a -80 ℃ freezer for at least 
1 hour. After thawing, we add 100 µL chloroform to each sample, shake vigorously for 15 
seconds, incubate at RT for 3 minutes, and then spin at 4 ℃ at 12000 g. The aqueous, 
chloroform phase we transfer to a fresh tube on ice and. 1 µL of GlycoBlue™ (Life 
Technologies) is added to each sample, then 250 µL of isopropanol is added, and then 
incubated at least an hour at -80 ℃. After thawing, the samples are centrifuged at 12000 g at 
4 ℃ for 20 minutes. The supernatant is removed and discarded and then the samples are 
washed with 500 µL 75% cold ethanol and then centrifuged at 7400 g at 4 ℃ for 15 minutes. 
The ethanol is removed and the pellet allowed to air dry. Each pellet is resuspended in 12.5 µL 
Nuclease-free water, incubated at RT for 3 minutes, placed on ice and quantified for RNA 
content using a Nanodrop spectrophotometer."
"
cDNA synthesis and qPCR!
cDNA is prepared using the SuperScript® Vilo cDNA synthesis kit (Life Technologies) 
according to manufacturer’s instructions. qPCR is performed using the TaqMan® probe set for 
mouse TRPV1 (Mm01246302_m1) and GAPDH (Mm03302249_g1) as control, following 
manufacturer’s instructions (Life Technologies). Fold changes were calculated using the 
comparative CT method33: "
 such that = (Ctreatment_gene - Ctreatment_standard) - (Ccontrol_gene - Ccontrol_standard)."
"
""
2−(ΔΔCT ) ΔΔCT
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RESULTS""
TRPV1 activation and sensitization is detectable in a parallel-based imaging system!
We examined the effectiveness of the FDSS7000EX (Hamamatsu) dynamic calcium-imaging 
machine in discerning the sensitization of TRPV1 in vitro. The advantage of using DRG 
neurons is the relatively intact signaling pathways with effector proteins as well as natural 
expression of TRPV1 on the membrane. Our plating strategy was based on previous 
experiments showing that 2000 cells per well and 100 nM - 1 µM capsaicin led to the highest 
calculated z-scores35. Hypothesizing that sensitization would cause not only increases in 
signal from those cells apt to respond, but also responses in cells that would normally not 
respond at lower concentrations, we used 100 nM capsaicin as the concentration at which we 
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Figure 3.1 - High-throughput sensory neuron imaging. (A) The scale of the 384-well plate setup, 
showing a blown-up figure of DRG neurons illuminated by fluorescent dye in one portion of a dish. 
The cells are plated at 2000 neurons/well. (B) Representative traces of activation of wells using 
high and low capsaicin (1 µM, 100 nM) and KCl (40 mM, 5 mM). (C) Sensitization of capsaicin 
responses (100 nM) following short-term sensitization via PGE2 (10 minutes at 30 µM). (D) Basic 
composition of the ScreenWell® ICCB Known Bioactives Library (BioMol).
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interrogated our system. Figure 3.1A demonstrates the scale of this protocol. At a plating 
density of 2000 cells per well, we achieved discernible signal for low (100 nM) and high (1 µM) 
concentrations of capsaicin, as well as very strong responses to low (5 mM) and high (40 mM) 
KCl (Figure 3.1B). High KCl activates all neurons in culture, whereas capsaicin activates 
about half of neurons at the maximal concentration (1 µM). "
"
We employed a novel approach in examining TRPV1 sensitization: combining parallel 
processing with a long-term pre-sensitization, independent of desensitization. To cover as 
much ground as possible, we initiated a 480-compound screen in our 384-well system of a 
diverse body of drugs, all with robust literature-based annotation associated with them (For 
general categories: Figure 3.1D, for complete list:  http://iccb.med.harvard.edu/biomol-known-
bioactives-2012-list-of-compounds/)."
"
Many chemotherapeutic agents cause sensitization of TRPV1!
Of particular note was the high prevalence of chemotherapeutic agents among the top 
sensitizing agents (Figure 3.2C and Supplementary Figure 3.1). This is particularly 
important in recognition of one of the common adverse events of many chemotherapeutics: 
neuropathy which is frequently painful. The mechanisms of chemotherapy-induced 
neuropathic pain are poorly understood and there is no effective treatment36. TRPV1 function 
has been implicated in part, but otherwise very little is known relative to TRPV1 activity in the 
context of chemotherapy-induced neuropathy36,37. "
"
Of three proteasome inhibitors included in the BioMol (MG-132, Z-Leu3-VS, and gliotoxin), all 
three were represented in the most likely candidates to cause sensitization of TRPV1 (Figure 
3.2B and Figure 3.3)38-40. Bortezomib (AKA Velcade™ or PS-341) has recently been 
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approved by the FDA (2003) for the treatment of multiple myeloma and was the first-in-class 
proteasome inhibitor allowed on the market41. Roughly half of all patients taking bortezomib 
develop neuropathy43. Bortezomib is a peptide boronic acid, analogous to a common class of 
protease inhibitors, aldehyde peptides44. It inhibits the 26S proteasome complex with a high 
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Figure 3.2 - Unbiased large-scale experiment uncovers the proteasome inhibition as potential 
mechanism for TRPV1 sensitization. (A) Complete, ranked results of well responses in FDSS7000EX. 
Each point is an average of the two experiments run after 24 hours of incubation with test compounds. 
% signal change represents the overall change in fluorescence intensity first normalized to initial 
intensity levels. (B) Closeup view of the top 8% of results showing top hits that are also 
chemotherapeutic agents. Proteasome inhibitors (Z-Leu3-VS (50 ng/mL), MG-132 (50 ng/mL), and 
gliotoxin (50 ng/mL)) are indicated by arrows. Bars connect both responses measured. (C) Grouped 
chemotherapeutic, or experimental analogs of chemotherapeutics modulate TRPV1 function. (D) Retrial 
of varying bortezomib concentrations demonstrates concentration response. PGE2 is a positive control 
for sensitization.
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degree of specificity; its Ki is less than 1 nM (~0.6 nM)44. The proteasome complex is 
responsible for the degradation of many cell-cycle regulatory proteins including cyclins, tumor 
suppressor genes (e.g. p53), oncogenes like c-myc, 
IκB, p130, and enzymes such as topoisomerase 
inhibitors44. The increased buildup of these would-be 
breakdown products leads to an increase in apoptotic 
activation. "
"
Fortunately neuropathy from bortezomib does resolve 
in most cases following cessation of treatment, 
however, the pain from the neuropathy frequently can 
be dose-limiting for cancer treatment45. "
"
Proteasome inhibition causes increased strength 
and amount of cells responding to low 
concentrations of capsaicin!
Bortezomib was not included in the initial screen, but 
due to its high incidence of neuropathy as well as the 
consistent results among other proteasome inhibitors in 
the screen, we focused our attention on this compound. 
By repeated tests in the FDSS 7000EX (Hamamatsu) 
we see a concentration-dependent onset of TRPV1 sensitization (Figure 3.2D). Using 
traditional microscope-based calcium imaging with the ratiometric dye, fura-2, we saw marked 
changes in neuronal responses as well. "
"
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Figure 3.3 - Structures of 
proteasome inhibitors that cause 
TRPV1 sensitization. Gliotoxin (50 
ng/mL), MG-132 (50 ng/mL), and Z-
Leu3-VS (50 ng/mL) were in original 
screen and showed capsaicin-
sensitization effect. Bortezomib is a 
clinical tool that also causes 
sensitization of TRPV1.
By adding the compound, and then assessing TRPV1 sensitivity to a low-concentration 
capsaicin challenge (30 nM) 24 hours later, we examined strength of responses, amount of 
cells responding, and the time to activation of response. We used a concentration of 
bortezomib (100 nM) roughly equivalent to early plasma concentrations following 
administration of the drug in human patients46. We exposed the cells to a sub-maximal 
concentration of capsaicin (30 nM) and compared these responses to the response following a 
 46
Non-treated control DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
100nM bortezomib-treated DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
Average response among TRPV1+ DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0.0
0.5
1.0
1.5
2.0
2.5
30nM capsaicin 1mM capsaicin 40mM KCl
control
bortezomib 100nM
Proportion of DRG neurons responsive to
30nM capsaicin by time
time (seconds)
Pr
op
or
tio
n 
of
 T
R
PV
1+
 n
eu
ro
ns
0 10 20 30
0.0
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
Quantile-quantile plot of TRPV1+ DRG neurons
AUC-Control
AU
C
-1
00
nM
 b
or
te
zo
m
ib
0 20 40 60 80
0
20
40
60
80
CumulativeDistribution-Integral
AUC-trpv1+ cells
cu
m
ul
at
e 
fr
eq
ue
nc
y
-20 0 20 40 60 80
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
A B
C D
E F
Non-treated control DRG neurons
time (seconds)
dF
34
0/
F 3
80
60 120 180 240 300 360
-0.5
0.0
0.5
1.0
1.5
2.0
30nM capsaicin 1mM capsaicin 40mM KCl
Non-treated control DRG neurons
time (seconds)
dF
34
0/
F 3
80
60 120 180
-0.5
0.0
0.5
1.0
1.5
2.0
30nM capsaicin
Average time to activation of 30nM capsaicin
Ti
m
e 
to
 a
ct
iv
at
io
n
co
ntr
ol
10
0n
M 
bo
rte
zo
mi
b
0
5
10
15
****
Bortezomib (100nM) treated DRG neurons
time (seconds)
dF
34
0/
F 3
80
60 120 180
-0.5
0.0
0.5
1.0
1.5
2.0
30nM capsaicin
Slope of F340/F380
time (seconds)
dF
34
0/
F 3
80
60 120
-0.1
0.0
0.1
0.2
Control Slope
100nM bortezomib Slope
30nM capsaicin
Data 33
seconds to activation
cu
m
ul
at
e 
fr
eq
ue
nc
y
0 3 6 9 12 15 18 21 24 27 30
0.0
0.1
0.2
0.3
0.4
0.5
bort
cont
G
Non-treated control DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
100nM bortezomib-treated DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
Average response among TRPV1+ DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0.0
0.5
1.0
1.5
2.0
2.5
30nM capsaicin 1mM capsaicin 40mM KCl
control
bortezomib 100nM
Proportion of DRG neurons responsive to
30nM capsaicin by time
time (seconds)
Pr
op
or
tio
n 
of
 T
R
PV
1+
 n
eu
ro
ns
0 10 20 30
0.0
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
Quantile-quantile plot of TRPV1+ DRG neurons
AUC-Control
AU
C
-1
00
nM
 b
or
te
zo
m
ib
0 20 40 60 80
0
20
40
60
80
CumulativeDistribution-Integral
AUC-trpv1+ cells
cu
m
ul
at
e 
fr
eq
ue
nc
y
-20 0 20 40 60 80
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
A B
C D
E F
Non-treated control DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
100nM bortezomib-treated DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
Average response among TRPV1+ DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0.0
0.5
1.0
1.5
2.0
2.5
30nM capsaicin 1mM capsaicin 40mM KCl
control
bortezomib 100nM
Proportion of DRG neurons responsive to
30nM capsaicin by time
time (seconds)
Pr
op
or
tio
n 
of
 T
R
PV
1+
 n
eu
ro
ns
0 10 20 30
0.0
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
Quantile-quantile plot of TRPV1+ DRG neurons
AUC-Control
AU
C
-1
00
nM
 b
or
te
zo
m
ib
0 20 40 60 80
0
20
40
60
80
CumulativeDistribution-Integral
AUC-trpv1+ cells
cu
m
ul
at
e 
fr
eq
ue
nc
y
-20 0 20 40 60 80
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
A B
C D
E F
Non-treated control DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30nM capsaicin 1mM capsaicin 40mM KCl
100nM bortezomib-treated DRG neurons
ti e (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0
1
2
3
4
30n  capsaicin 1m  capsaicin 40  KCl
Average response among TRPV1+ DRG neurons
time (seconds)
F 3
40
/F
38
0
0 60 120 180 240 300 360
0.0
0.5
1.0
1.5
2.0
2.5
30nM capsaicin 1mM capsaicin 40mM KCl
control
bortezomib 100nM
Proportion of DRG neurons responsive to
30nM capsaicin by time
time (seconds)
Pr
op
or
tio
n 
of
 T
R
PV
1+
 n
eu
ro
ns
0 10 20 30
0.0
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
Quantile-quantile plot of TRPV1+ DRG neurons
AUC-Control
AU
C
-1
00
nM
 b
or
te
zo
m
ib
0 20 40 60 80
0
20
40
60
80
CumulativeDistribution-Integral
AUC-trpv1+ cells
cu
m
ul
at
e 
fr
eq
ue
nc
y
-20 0 20 40 60 80
0.2
0.4
0.6
0.8
1.0
control
bortezomib 100nM
A B
C D
E F
Figure 3.4 - 24 hour bortezomib treatment increases strength of 
response and amount of TRPV1+ cells responding. (A) Individual 
fura-2 based calcium tracings of DRG neurons in culture after 24 
hours. (B) Individual fura-2 based calcium tracings of DRG neurons 
treated with 100nM bortezomib for 24 hours. (C) Comparison of 
average tracing for all TRPV1+ cells under the conditions in panels 
(A) and (B). (D) Proportion of DRG neurons responsive to 30 nM 
capsaicin by time. Error bars represent standard error from 3-4 
different trials (E) Cumulative distribution of AUC calculations with 
capsaicin-based activation (30 nM). (F) Quantile-quantile plot 
demonstrating response increases across all quantiles when 
treated with bortezomib (100 nM). (G) The average time to respond 
among treated cells is significantly less than control (p < 0.0001 
student’s t-test, df = 392). Dashes represent standard error 
margins. Error bars in panels C and D represent SE. C averages all 
cells for each condition (Control n = 250, treated n = 283), while D 
is an average for 3 or 4 separate dishes.
high concentration of capsaicin (1 µM) after a brief wash-out period. Figure 3.4 (A & B) shows 
representative traces from control-treated DRG neurons and traces from bortezomib-treated 
(100 nM) for 24 hours.  "
"
By averaging the TRPV1+ cells’ responses, we see a markedly increased response to a low 
concentration of capsaicin following incubation with bortezomib (Figure 3.4C). Additionally, 
tracking the time at which each cell reaches a threshold response demonstrates the marked 
changes that bortezomib induces in DRG neurons (Figure 3.4D). The % response differences 
upon activation by 30 nM capsaicin across 30 seconds of activation in 3 second increments 
shows kinetic differences with the early differences in response % being the most striking. This 
difference in response kinetics can be summarized as a time to activation across all cells, 
which is nearly twice as fast among cells treated with bortezomib than those not treated 
(Figure 3.4G)."
"
To gain a greater appreciation for the onset of the effect of TRPV1 sensitization following 
bortezomib treatment, we modified the amount of time for treatment. Using 1 µM bortezomib, 
the response of treated cells to capsaicin relative to control increases rapidly with time. The 
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Figure 3.5 - Time dependency of TRPV1 sensitization following 
bortezomib-treatment. (A) Q-Q plots demonstrating time-
dependency of response to 1 µM bortezomib treatment: 1, 6, 24, 
48, and 72 hours. All x-axes are the AUC of control treated cells, y-
axes are the AUC of bortezomib-treated cells. (B) Area between the 
curve calculations from (A) showing the time dependency of 
response.
maximal effect is seen at 24 hours of treatment compared with 1 hour and 6 hours (Figure 
3.5). By 2 and 3 days, the difference between treated and untreated cells becomes much 
greater, however these changes are also marked by other effects on the culture as a whole. 
As DRG cultures are grown longer than a day, they typically become overrun by proliferating 
non-neuronal cells that also reside in the DRG. These cells are markedly reduced by 
bortezomib treatment (figure not shown). The timing and onset of sensitization and the 
additional effects of bortezomib on non-neuronal cells allows for the possibility of multiple 
mechanisms of action, direct and indirect. The elucidation of these mechanisms will be the 
focus of future studies. No expression level changes in mRNA were seen as assessed by 
qPCR for TRPV1 over these same time points (Figure 3.6)."
"
To examine the specificity of TRPV1 sensitization, we examined TRPA1 modulation as well as 
voltage-gated calcium channels following treatment with bortezomib (Figure 3.7). KCl 
activates voltage-gated calcium channels activating all TRPV1+ neurons, while AITC (allyl-
isothiocyanate, or mustard oil) activates the non-selective cation channel, TRPA1 (transient 
receptor potential ankyrin type 1) which is largely 
subsumed within the TRPV1+ population 47-49. 100nM 
bortezomib over 24 hours causes a roughly 20% increase 
in TRPV1-specific sensitization, while AITC and KCl 
responses drop by more than 40%. The opposite effect of 
bortezomib treatment on AITC and KCl demonstrates the 
sensitization effect of bortezomib on calcium flux is at 
least specific for TRPV1 relative to TRPA1 and voltage-
gated calcium channels."
"
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Figure 3.6 -  TRPV1 mRNA 
expression levels unmodified following 
treatment with 1uM. 
TRPV1 expression levels after incubation
with 1mM bortezomib
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Discussion!
Neuropathy has been estimated to occur in 1/3 of all patients who take chemotherapy50. The 
symptoms can be quite severe, particularly when the neuropathy is painful. Burning, 
paroxysmal pain or extreme hypersensitivity as a result of chemotherapy can be dose-
limiting51. Bortezomib affects about half of patients treated to varying levels of intensity, with 1 
out of 5 or 6 patients having severe neuropathy52,53. About 70% of patients recover from the 
neuropathy following cessation of treatment54,55."
"
Among the most common adjectives that patients use to describe the neuropathy following 
bortezomib treatment are: “numb”, “tingling”, “burning”, “cold”, “sharp” and “electric”56. It is 
noteworthy that patients actually become less sensitive to heat and more sensitive to cold, 
while “burning” is used to describe the pain in half of all patients. TRPV1, the heat channel is 
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Figure 3.7 - 100nM bortezomib treatment desensitizes KCl and AITC responses. (A) Average traces of 
non-treated DRG neuronal responses as measured by the FDSS7000EX. (B) Average traces of DRG 
neuronal responses after 24 hour treatment with 100nM bortezomib. (C) % sensitization for each 
condition represented. Capsaicin responses were increased, while KCl and AITC responses are 
significantly desensitized. Error bars represent standard error.
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potentially playing a central role in the genesis of the pain in this condition, as well as a role in 
the actual development of neuropathy.  "
"
We used a high-throughput and unbiased approach to discover that proteasome inhibitors, 
including the clinical compound, bortezomib, cause TRPV1 sensitization. The high rate of 
bortezomib-induced neuropathy is a serious clinical problem and needs further study. An 
immediate role for TRPV1 in the cause of pain can be established quickly by trying TRPV1 
antagonists or agonists as a treatment. Perhaps more fundamental a question regarding the 
role of TRPV1 is whether TRPV1 plays a role in the pathogenesis of the bortezomib-induced 
neuropathy itself. Could calcium-overload via TRPV1 result in increased apoptosis? With 
bortezomib-use on the rise, understanding the mechanisms of neuropathy is a critical issue."
""
TRPV1 is a critical gateway for pain, and while not all pain travels down the same neuronal 
circuitry, previous experience with two other chemotherapeutics: cisplatin and paclitaxel, 
shows that TRPV1 plays a critical role in the painful aspects of chemotherapy-induced 
neuropathy37,57-59. The unbiased approach of using a high-throughput screening system has 
demonstrated here TRPV1 sensitization not only after bortezomib, but also following several 
different chemotherapeutics that cause neuropathy as well as a high proportion of  the 
endpoint of TRPV1 following chemotherapeutic intervention, yet also demonstrates more of 
the function of TRPV1 sensitization. KCl activation has been used as an indicator in our 
experiments of overall cell health and viability. Chemotherapeutic agents drastically lower the 
responses within our system to KCl, while increasing responses through TRPV1. Does TRPV1 
serve a role as warning sensor for internal damage and apoptosis driven by toxic chemicals or 
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otherwise? Or, is  TRPV1 actually participating in the development of pain at the least, and 
possibly neuropathy itself? This is a particularly intriguing and important question."
"
Ionic disregulation, mitochondrial impairment and apoptotic pathway activation are all 
implicated in what is currently an unsorted and not completely clear view on the mechanisms 
of chemotherapy-induced neuropathy60. To the point of ionic disturbance in general as a 
mechanism for neuropathy is recent evidence arguing for a direct role of sodium channel 
mutations in the spontaneous development of neuropathy61,62. As for a greater role of TRPV1 
sensitization in the pain and/or neuropathy generation, it is interesting to note that one of the 
effects of multiple myeloma, the primary indication for bortezomib treatment, is 
hypercalcemia42. Additionally, a small proportion of patients with multiple myeloma develop 
neuropathy without any chemotherapeutic intervention, inviting the question: how do plasma 
calcium levels in the face of multiple myeloma correlate with neuropathy during bortezomib-
treatment? Perhaps it is the combination of calcium overload, TRPV1 sensitization and 
mitochondrial and ER stress (limiting the cellular capacity for calcium sequestration) that lead 
to selective damage of DRG neurons. It was previously shown that ruthenium red, a non-
selective pore-blocker of TRP channels provides some cellular protection against apoptosis63. 
TRPV1, a sensitized non-selective cation channel could be the gate by which calcium initiates 
the apoptotic pathway, particularly in the case of mitotoxicity - leading to pain as well as 
neuropathy64. "
"
Additional experiments will be necessary to demonstrate the role of TRPV1 in bortezomib’s 
neurotoxic effects. By comparing DRG neurons, axons, intra-epidermal nerve fibers, as well 
as the assortment of non-neuronal supporting cells in bortezomib-treated mice who are 
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TRPV1 deficient (pharmacologically or genetically) should lend useful insights to 
understanding the bortezomib-induced neuropathy."
"
We initiated the experiments described here by utilizing a high-throughput system to examine 
TRPV1 sensitization. In an unbiased manner, we found that several chemotherapeutic 
compounds cause TRPV1 sensitization, including bortezomib, a proteasome inhibitor. 
Hopefully, by following up on the other leads as well, we can develop a more complete picture 
of TRPV1 sensitization and relevance to disease."
"""
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"
Chapter 4: Photochemical activation of TRPA1 channels in neurons and animals* ** !34
"
Abstract!
Optogenetics is a powerful research tool because it enables high-resolution optical control of 
neuronal activity. However, current optogenetic approaches are limited to transgenic systems 
expressing microbial opsins and other exogenous photoreceptors. Here, we identify optovin, a 
small molecule that enables repeated photoactivation of motor behaviors in wild-type zebrafish 
and mice. To our surprise, optovin’s behavioral effects are not visually mediated. Rather, 
photodetection is performed by sensory neurons expressing the cation channel TRPA1. 
TRPA1 is both necessary and sufficient for the optovin response. Optovin activates human 
TRPA1 via structure-dependent photochemical reactions with redox-sensitive cysteine 
residues. In animals with severed spinal cords, optovin treatment enables control of motor 
activity in the paralyzed extremities by localized illumination. These studies identify a light-
based strategy for controlling endogenous TRPA1 receptors in vivo, with potential clinical and 
research applications in nontransgenic animals, including humans."
INTRODUCTION"
One of the most influential recent innovations in neuroscience has been optogenetics, an 
approach for controlling neurons with exogenous microbial opsins or other ectopic 
* The chemical and zebrafish work for this study was performed in the laboratory of Randall Peterson at 
Massachusetts General Hospital, Boston. I worked on confirming the specificity of optovin for activating 
TRPA1 in WT and TRPA1-/- primary dorsal root ganglia cells via calcium imaging that I dissected and 
cultured. I showed that optovin was not effective in activating 3CK mutant HEK cells with additional 
assistance from Ajay Yekkirala and Cleverton Kleiton Freitas de Lima. Additionally, I developed and 
performed the assay to see optovin-based behavioral responses in mice in the Woolf Laboratory at 
Children’s Hospital, Boston with advice and assistance from Ajay Yekkirala and David Roberson.
** This chapter is a modified version of an article previously published as: Kokel, D., Cheung, C.Y.J., 
Mills, R., Coutinho-Budd, J., Huang, L., Setola, V., Sprague, J., Jin, S., Jin., Y.N., Huang, X-P., Bruni, G., 
Woolf, C.J., Roth, B.L., Hamblin, M.R., Zylka, M.J., Milan, D.J., & Peterson, R.J. Photochemical 
activation of TRPA1 channels in neurons and animals. Nat. Chem. Biol. 9, 257–63 (2013).
photosensitive channels1–11. Optogenetic techniques in model organisms are yielding 
remarkable new insights in neuroscience and medicine. However, current approaches do not 
address the unmet need for controlling endogenous neuronal proteins and neuronal signaling 
in nontransgenic animals with light. "
Photochemical tools for controlling endogenous channels in vivo enable powerful approaches 
for neuroscience research and therapeutic intervention12. For example, photorelease of caged 
glutamate provides optical control of glutamate receptors in brain slices. Azobenzene-
containing photoswitchable ligands also provide optical control of glutamate receptors and 
potassium channels9,10,12–19. However, virtually all prior work in chemical optogenetics has 
been limited to cultured cells, tissue slices and other ex vivo preparations because most 
existing techniques are not effective in vivo. Discovery of new compounds with higher potency 
and better in vivo properties would improve the photochemical ligand toolbox. Here, we used 
behavior-based chemical screening to identify optovin, a new photochemical switch compound 
with potent bioactivity in intact living animals."
Receptors in the transient receptor potential (TRP) family are attractive channels for bringing 
under optical control20. TRP channels are involved in diverse sensory systems including 
vision, taste, temperature and touch. TRPA1 signaling contributes to illnesses, including 
neuropathic pain and chronic inflammation21–24. Precise control of TRPA1 channels may be 
useful for understanding and treating these disorders. However, currently available TRPA1 
ligands such as mustard oil and cinnamaldehyde provide imprecise spatiotemporal control of 
TRPA1 signaling."
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Here, we used a behavior-based chemical screening approach to identify optovin, a new 
neuroactive small molecule. Optovin is a TRPA1 ligand that can be reversibly photoactivated 
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Figure 4.1 - Identification of optovin, a compound enabling light-mediated neuronal excitation. (a,b) 
Plots showing the zebrafish behavioral response of DMSO-treated (a) and optovin-treated (b) animals. 
The bar indicates the timing of a 1-s white light stimulus. (c) Scatter plot showing the behavioral 
excitation scores from chemicals in the screen (12,500 individual wells). The y axis represents the 
number of s.d. of each excitation score from the control mean (Z score). The labeled arrow indicates the 
well treated with optovin. (d) Dose response curve showing optovin’s effects on animal behavior (EC50 
= 2 M; n = 5). The difference between the 1-M and 3-M treatments is significant, P < 0.001. (e) Line plot 
showing excitation scores at the indicated stimulus intensities (n = 5). The difference between groups 
treated at 1.6 W mm−2 and 2 W mm−2 is significant, P < 0.001. (f) Bar plot showing behavioral 
responses to repeated light stimuli (n = 5). Differences between treated and untreated groups are 
significant, P < 0.001. Error bars represent s.d."
by violet light. Optovin’s behavioral effects depend on TRPA1 and it shows activity in 
zebrafish, mice, mouse neurons and recombinant human protein. The photochemical reaction 
mechanism most likely involves reversible covalent thioether bonding between TRPA1 and 
optovin. Optovin is the first known photochemical TRPA1 ligand, and it enables optical control 
of neurons that express this target in wild-type animals."
RESULTS 
Behavior-based chemical screening identifies optovin"
To identify small molecules for the optical control of endogenous channels, we screened for 
compounds that could drive light-dependent motor behaviors in wild-type zebrafish. Zebrafish 
embryos are uniquely well suited for phenotype-based chemical screens25,26. They are blind 
for the first 3 d of development, and, aside from a one-time motor response to the first light 
exposure in dark-adapted animals (the photomotor response (PMR)), zebrafish embryos are 
unresponsive to light27,28 (Figure 4.1a). We screened a library of 10,000 structurally diverse 
synthetic small molecules for compounds that render zebrafish embryos responsive to light. 
Behavioral responses were measured for each well in comparison to a set of 2,500 DMSO-
treated controls. This screen identified a single compound, optovin, which increased motor 
activity greater than 40 s.d. above the control mean (Figure 4.1a–c)."
Optovin is a rhodanine-containing small molecule with no previously annotated biological 
activity. Whereas DMSO-treated animals do not respond to photic stimuli, optovin-treated 
animals respond to light with vigorous motor excitation at a half-maximum excitatory 
concentration (EC50) of 2 µM (Figure 4.1d). Motor behavior in optovin-treated animals (387 
nm) is elicited by stimulus intensities greater than 1.6 W mm−2 (Figure 4.1e). In treated 
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animals, multiple responses can be triggered with repeated light pulses (Figure 4.1f). To 
determine the effects of optovin exposure on development, behavior and survival, we 
analyzed zebrafish exposed to optovin (10 µM) for 96 h. We did not identify any differences in 
the appearance, touch response, heart rate, fin movements, morphology or percentage 
survival between the treated and untreated groups (data not shown). Thus, optovin is a new 
behavior-modifying compound that causes rapid and reversible motor excitation in response to 
violet light stimuli."
To gain initial insight into optovin’s mechanism of action, we profiled optovin using the National 
Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) to determine 
its activities against a panel of human and rodent CNS receptors, channels and transporters. 
No submicromolar targets were identified (data not shown), suggesting that optovin may act 
through a mechanism of action not represented in the extensive NIMH PDSP collection."
TRPA1 is necessary and sufficient for optovin activity!
Optovin-treated zebrafish embryos respond to light at very early stages of development, 
before the eye and vision develop. The observation that animals respond prior to the onset of 
vision suggests that the optovin response is a nonvisual behavior and that optovin acts on 
tissues other than the eye. To determine whether the eyes are necessary for the optovin 
response, we compared the responses of intact zebrafish embryos to the trunks of age-
matched spinalized preparations transected posterior to the hindbrain. Sensory neurons in the 
trunk normally respond to various kinds of touch, stretch, temperature and pain but not to light. 
To our surprise, we found that optovin-treated spinalized preparations also responded to light 
(Figure 4.2). Using a 405-nm laser beam, we observed optovin-dependent motor responses 
to illumination of the trunk, tail and fins, which are all sites innervated by sensory neurons. 
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Together, these data indicate that visual pathways are not necessary for the optovin-induced 
light response and suggest that optovin may act on sensory neurons."
To determine whether optovin acts on sensory neurons, we used calcium imaging to compare 
the activity of treated and untreated dorsal root ganglia (DRG) sensory neurons isolated from 
wild-type mice. We found that optovin strongly activated 33% (35/105) of DRG neurons 
(Figure 4.3a). This activation did not occur when optovin treatment occurred in the dark 
(Figure 4.4a–d). To determine whether optovin activates neurons that also respond to known 
ligands, we treated the DRG neurons with mustard oil, a TRPA1 ligand30. We found that 
mustard oil activated 27% (28/105) of DRG neurons and that nearly all DRG sensory neurons 
that responded to mustard oil also responded to optovin (27/28; Figure 4.4b,d,e). These data 
suggest that optovin acts on a molecular target expressed in mustard oil–responsive 
mammalian DRG sensory neurons and perhaps on TRPA1 itself."
TRPA1 channels have important roles in detecting chemical, thermal and mechanical stimuli in 
a variety of organisms31–33. The zebrafish genome encodes two orthologs of the mammalian 
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Figure 4.2 - Optovin-treated spinalized preparations respond to light. (a) Behavioral excitation scores of 
intact and spinalized zebrafish embryos (30 hpf). Differences between treated and untreated groups are 
significant, p<0.001. Photographs showing zebrafish embryos at 35hpf before (b) and after (c) 
transection posterior to the hindbrain as indicated by the dashed line. Scale bar, 150 μm. (d,e) 
Examples of how DMSO-treated (c) and optovin-treated (d) spinalized animals respond to light stimuli."
TrpA1 gene, designated trpa1a and trpa1b, which have different expression patterns and 
functions34. To test the hypothesis that optovin acts on TRPA1, we analyzed the behavior of 
trpa1a and trpa1b mutant animals. As expected, we found that wild-type zebrafish responded 
to optovin and the 387-nm light stimulus with a prolonged motor excitation (Figure 4.3b,c). By 
contrast, mutant fish homozygous for trpa1b failed to respond (Figure 4.3b,c). Notably, dark-
adapted trpa1b mutant fish still showed normal control behaviors, such as the PMR and the 
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Figure 4.3 - TRPA1 is necessary and sufficient for the optovin response. (a) Percentage of mouse DRG 
neurons responding to the indicated treatments. In the wild type (WT), the light stimulus activated 30% 
of neurons assayed (35/105). In the TRPA1 knockout (KO) neurons, the total percentage of responding 
neurons was 2.7% (8/291). MO, mustard oil. (b) Behavioral excitation scores during the optovin 
response for zebrafish 25 of the indicated genotypes. Het, heterozygous. (c) Behavioral excitation 
scores calculated for wild-type, heterozygous and homozygous TrpA1b mutant animals (n = 21, 23 and 
16, respectively) during the PMR (control) and optovin response assays. Homozygous mutant animals 
show a significantly lower activity during the optovin response assay, P < 0.001. (d) Bar plot showing 
calcium indicator dye fluorescence in cells transfected with GFP or hTrpA1 before and after a 2-min 
treatment with optovin and light (n = 130 and 120 cells, respectively). The difference between treated 
and untreated hTRPA1-transfected cells is significant, P < 0.001."
touch response, indicating that the trpa1b mutation does not suppress motor behaviors in 
general (data not shown). These data indicate that trpa1b is necessary for the optovin 
response in zebrafish. To determine whether the gene encoding TRPA1 is also necessary for 
the optovin response in mice, we analyzed the activity of DRG neurons isolated from TrpA1 
mutant mice11. Unlike wild-type controls, TrpA1 mutant neurons did not respond to either 
mustard oil or optovin, although they did respond to KCl, a depolarizing agent (Figure 4.3a). 
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Figure 4.4 - Mustard oil and optovin act on the same subset of DRG sensory neurons. (a-c) Calcium 
imaging of mouse DRG neurons in response to vehicle (a), optovin and light (b), and optovin without 
light (c). Black traces indicate calcium indicator fluorescence readings. No readings were recorded 
during the 1min optovin treatment period in c) when lights were turned off. (d) Fuorescence traces from 
10 example cells showing their response to the indicated treatments. (e)Venn diagram showing that 
28/35 mustard oil responsive cells also respond to optovin. (f) After Fura-2, AM loading and washing, 
neurons were loaded with optovin (100 μM) and with either the TRPA1 antagonist, HC-030031 (26 μM, 
Sigma) (McNamara et al., 2007) or vehicle control (DMSO, 0.025%). After a 10-minute incubation 
period, the neurons were exposed to a 5-second laser pulse (405 nm), washed, and then activated with 
mustard oil (100 μM). Responses are presented normalized to the response elicited by mustard oil per 
Furthermore, HC-030031, a selective TRPA1 antagonist35, blocked optovin activity on wild-
type mouse DRG neurons (Figure 4.4f). Together, these data suggest that TrpA1 is necessary 
for the optovin response."
Optovin is a reversible photoactivated TRPA1 ligand!
Does optovin and light activate TRPA1 in a manner similar to mustard oil, through a few 
critical cysteine residues? The triple cysteine mutant (3CK) channel is relatively unresponsive 
to mustard oil, but responsive to carvacrol, another TRPA1 agonist that works through a 
different mechanism (Bessac et al., 2008). Activation with optovin of this mutant channel was 
relatively ineffective (Figure 4.5). Together, these data suggest that optovin activates TRPA1 
channels in a manner similar to mustard oil."
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Figure 4.5 - Optovin has no activity on the hTrpA1 3CK triple cysteine mutant. (a) 3CK mutant 
TRPA1 plasmid (provided by Christian von Hehn) was transfected into HEK- 293 cells and imaged 
using Fura-2, AM (Life Technologies) the mutations replace the residues on C619, C639, C663, 
and K708 to serine residues (Escalera et al., 2008). Laser alone, MO alone (100 μM) and optovin 
(100 μM) and laser combined were used to elicit activation. Carvacrol (100 μM, Sigma-Aldrich) was 
used as a positive control as it is an agonist of TRPA1 which does not depend on the cysteine 
residues otherwise critical for MO-based activation (Hinman et al., 2006) (n= 41 cells)."
Photochemical control of optovin-treated animals!
Optovin’s capacity to function in intact adult animals will affect its potential for use in future 
clinical and research applications. Thus, we analyzed the effects of 405-nm laser illumination 
on optovin-treated adult animals. In zebrafish, we found that illuminating the dorsal fin elicited 
rapid and reversible contraction of the fin but did not seem to otherwise disturb the treated 
animal. To determine whether fin contraction was voluntary or involuntary, we repeated the 
experiment using spinalized preparations. Optical control of dorsal fin contraction was 
preserved in spinalized animals treated with optovin (Figure 4.6a). Furthermore, we found that 
carefully controlled laser illumination of specific regions along the body of spinalized zebrafish 
produced specific dorsal, ventral and lateral tail movements reminiscent of those used by 
intact fish during swimming (Figure 4.6b). Because zebrafish TRPA1 is primarily expressed in 
sensory neurons, these contractions and swimming behaviors most likely occur via activation 
of spinal reflex arcs. These data indicate that optovin enables real-time optical control of 
neurons in adult wild-type vertebrate animals. We found that optovin also elicited head-
shaking behaviors in adult mice (Figure 4.6c). Thus, optovin shows activity in adult animals in 
vivo and may be preferable to conventional TRPA1 ligands for achieving high-resolution 
spatiotemporal control."
DISCUSSION!
These studies have identified optovin, a small molecule that enables optical control of 
endogenous channels and neuronal signaling in wild-type nontransgenic animals. Optovin 
differs from previously identified photochemical switch compounds in several ways. Optovin 
acts on TRPA1 channels, which were previously inaccessible via optical techniques. Unlike 
reversibly caged glutamate and photoswitchable affinity label compounds, optovin is not 
based on azobenzene photoreactivity. In addition, optovin can be washed out and seems to 
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be quite selective in its activity, with no substantial activity at dozens of other potential targets 
tested."
Optovin was discovered in a behavior-based chemical screen. As with most compounds 
discovered in phenotype-based screens, determining optovin’s mechanism of action has been 
a central focus of our studies. Through genetic, molecular and imaging-based experiments, 
we have identified that optovin acts on the cation channel TRPA1 most likely in peripheral 
neurons. Several lines of evidence indicate that TRPA1 channels are both necessary and 
sufficient for optovin function: (i) Genetic mutation of TrpA1b in zebrafish completely 
eliminates optovin’s activity. (ii) In a heterogeneous population of mouse DRG neurons, all 
optovin-responsive neurons also respond to the TRPA1 agonist mustard oil. (iii) Nonexcitable 
cultured cells can be rendered light sensitive by transfection with the gene encoding hTrpA1. 
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Figure 4.6 - Remote control of optovin-treated animals. (a) Photographs of spinalized zebrafish before 
and after photo-stimulation of the dorsal fin. Scale bar, 2.5 mm. (b) Photographs of spinalized zebrafish 
responding to laser photostimulation. Arrowheads indicate approximate location of the 405-nm laser 
point stimulus. Scale bar, 5 mm. (c) Male C57Bl/6 mice were given an optovin (15 mM) or vehicle 
(DMSO) swab on one ear. A low-power laser (405 nm) was trained on that ear, and time to a 
characteristic head shake or head twitch was measured. The difference between groups is significant (P 
< 0.05). Values are averages s.e.m."
Together, these data suggest that optovin specifically targets TRPA1 to enable the light-based 
control of sensory neurons."
Illumination of many small molecules, including optovin, can produce singlet oxygen or other 
ROS. Nevertheless, TRPA1 does not seem to simply respond to optovin-generated singlet 
oxygen because none of the efficient singlet oxygen-generating compounds that we tested 
caused any behavioral excitation in zebrafish. Instead, we favor the hypothesis that optovin 
directly binds TRPA1 and forms a photodependent and reversible covalent adduct, perhaps 
through a radical coupling with a cysteine residue in TRPA1. Olefins such as the one found in 
optovin’s unsaturated rhodanine system are known to react with cysteines under physiological 
conditions43,44. In addition, alterations to optovin or TRPA1 that would prevent cysteine adduct 
formation reduce optovin activity: methylation of optovin’s olefin substantially reduces its 
activity, as does mutation of presumptive target cysteines in TRPA1. These data are 
consistent with formation of a thioether linkage between TRPA1 and optovin."
A precedent exists for specific and reversible formation of cysteine adducts between small 
molecules and their targets. A series of electron-deficient olefins was recently shown to 
undergo rapid thiol addition reactions with a cysteine in their target kinase. The resultant 
thioether adducts are short lived, with the reverse reaction (thiol elimination) occurring 
spontaneously on timescales ranging from subseconds to seconds44. In another example that 
is perhaps even more analogous, flavin mononucleotide (FMN) is bound noncovalently by 
light, oxygen or voltage (LOV) domain– containing proteins45. Illumination with blue light 
excites FMN to the triplet state such that the C(4a) carbon of FMN reacts with a nearby 
cysteine in the LOV domain, forms a covalent adduct and alters the protein structure and 
function. This thioether adduct is also spontaneously reversible on the timescale of seconds. 
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In both of these examples, noncovalent interactions are necessary to bring the small molecule 
into close proximity to the target cysteine, where a transient thioether linkage forms 
spontaneously (electron-deficient olefins) or upon photoactivation (FMN). That structure-
directed induced-proximity may also be necessary in the case of optovin is supported by the 
fact that 171 similar rhodanines in our screening collection did not activate TRPA1 during the 
screen."
If optovin forms a thioether linkage with TRPA1, it seems to be photodependent and 
reversible. Its photodependence is suggested by the fact that even high concentrations of 
optovin do not elicit a behavioral response in zebrafish in the dark. Furthermore, when 
zebrafish or DRG neurons are treated with optovin and rinsed before illumination, no 
excitation is observed. Therefore, optovin does not seem to modify TRPA1 in the absence of 
light. After illumination, excitation is sustained for several seconds, and different optovin 
derivatives sustain excitation for differing lengths of time after illumination ends, from about 1 s 
(4g6) to more than 9 s (6b8). These observations are consistent with the idea that termination 
of excitation is mediated by reversal of the thioether adduct formation and that structural 
features of the optovin derivatives control the rate of reversal. More extensive analysis will be 
required to elucidate the factors that influence the reversal rate."
It will be interesting to learn whether optovin-like molecules can be used for controlling 
endogenous receptors in organisms other than zebrafish and mice. We have shown that 
optovin activates TRPA1 from zebrafish, mouse and humans and that optovin elicits light-
dependent behaviors in zebrafish and mice. Optovin’s activity in gating human TRPA1 in 
transfected cells suggests that it could, in theory, be applied to humans, but development of 
these compounds for therapeutic applications will require further chemical optimization. For 
example, rhodanine-containing compounds have been characterized by some as too reactive 
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for direct clinical development, and only one rhodanine-containing compound is in current 
clinical use45. Therefore, the safety of optovin-like compounds in humans will need to be 
evaluated. Nevertheless, the ability to control endogenous TRPA1 channels in vivo raises a 
number of therapeutic possibilities ranging from pain relief to spinal trauma therapy. Although 
optovin’s activity seems largely restricted to TRPA1-expressing neurons, additional screening 
may identify next-generation compounds targeting a wide range of targets in different 
excitable cell types, including cardiac cells. Such tools would have applications ranging from 
basic neuroscience research to clinical interventions."
"
METHODS"
Aquaculture !
A large number of fertilized eggs (up to 5,000 embryos per day) were collected from group 
mating of Ekkwill or TuAB zebrafish. Embryos were raised in HEPES (10 mM) buffered E3 
media in a dark incubator at 28 °C until 30 h.p.f. Groups of approximately eight embryos (28 
h.p.f.) were distributed into the wells of flat = bottom black-walled 96-well plates filled with E3 
medium (360 l). Embryos were then incubated in a dark incubator at 25 °C for chemical 
treatment and subsequent experiments. All zebrafish protocols were approved by the 
Institutional Animal Care and Use Committee at Massachusetts General Hospital."
Chemical libraries and treatments "
The Actiprobe library (TimTec) contains 10,000 compounds dissolved in DMSO at a stock 
concentration of 1mg/ml (~3 mM). The library was screened at a 1:300 dilution in E3 buffer for 
a final concentration of ~10 µM. Negative controls were treated with an equal volume of 
DMSO. Stock solutions were added directly to zebrafish in the wells of a 96-well plate, mixed 
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and allowed to incubate for 2–10 h in the dark before behavioral evaluation in the PMR assay. 
The library (10,000 compounds) was purchased from the TimTec corporation. The 
neurotransmitter library (700 compounds; cat. no. 2810) was purchased from Biomol 
International. Reordered hit compounds were dissolved in DMSO and added to wells as 
described above. Ordering information: optovin (ST52606; TimTec), analog 6b8 (5707191; 
Chembridge), 6c1 (6092141; Chembridge), 6c5 (118192; Sigma), 6c7 (6211600; 
Chembridge), 6c2 (6176046; Chembridge), 6c3 (6206065; Chembridge), 6c4 (7030539; 
Chembridge), 4g6 (ST025379; TimTec). Reordered compounds were used as received; MS/
NMR data were not collected to confirm their identities."
PMR behavioral assay "
Animals were exposed to a two-pulse stimulus train with a 10-s interstimulus interval. 
Exposure to the first pulse was used to trigger the PMR, which has a refractory phase of 
approximately 10 min. Untreated animals do not respond to the second pulse of light, so motor 
activity after the second pulse was used to assay for optovin activity. In a typical assay, 1,000 
frames of digital video were recorded at 33 f.p.s. using a camera (Hamamatsu ORCA-ER) 
mounted on a microscope (Nikon TE200) with a 1× objective. Instrument control and data 
measurement were performed using custom scripts for Metamorph Software (Molecular 
Devices). Each video was saved for review. Light stimuli were generated with a 300-W xenon 
bulb housed in a Lambda LS illuminator (Sutter) and delivered to the well 10 s and 20 s after 
the start of each video. A cold mirror (reflectance between 300 nm and 700 nm) on the 
illuminator was used to block wavelengths outside of this range. Light intensity was measured 
using a PM100D power meter attached to a S120VC photodiode power sensor (Thorlabs). 
Filters were used to restrict the excitation light to the indicated wavelengths."
Spinalized preparations "
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Adult zebrafish (0.5–1.5 years) were briefly anesthetized in ice water and quickly decapitated 
with a sharp razor blade. Spinalized preparations were incubated in optovin (50 µM) for 1–2 
min before testing with laser light stimuli (405 nm, 400 W mm−2)."
Behavioral analysis "
To analyze digital video recordings, custom software scripts were used to automatically draw 
six evenly spaced line segments across each well such that each embryo is likely to be 
crossed by one of the lines. The software then tracks the average intensity of the pixels for 
each segment over time. As the embryos move, the light intensity at some of the pixels 
changes. The motion index was calculated by taking the total absolute difference in pixel 
intensity between frames. This motion index correlates with the overall amount of motion in 
the well, both in terms of contraction frequency and number of animals in motion. Behavioral 
features are quantified by ‘excitation scores’ that are calculated by taking the 75th percentile 
of the motion index for 3–5s following the light stimulus. The behavioral profiles were clustered 
using Euclidean distance and average linkage clustering. All computations and figures were 
carried out with the MATLAB statistical programming environment."
Statistical analysis!
We used one-way ANOVA and the Tukey HSD post hoc test to test for significant differences 
between groups, generate 95% confidence intervals and identify groups with significantly 
different means. For groups with significant differences, we used the two-tailed t-test to test 
the null hypothesis and calculate the P value. Statistical analyses were performed using the 
anova1, multcompare and ttest2 functions provided by the MATLAB statistics toolbox."
Electrophysiology "
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HEK293 cells were plated upon polylysine-coated cover slips and transiently transfected with 
human TRPA1. Voltage clamp recordings were made in the whole-cell configuration 48 h after 
transfection using glass electrodes with 2-4 MΩ resistance when filled with 140 mM CsCl, 2 
mM Mg2ATP3, 2 mM MgCl, 5 mM EGTA and 10 mM HEPES (pH adjusted to 7.2 with CsOH) 
and while bathed at room temperature in extracellular solution containing 150 mM NaCl, 5.4 
mM KCl, 1.8 mM CaCl2, 1 mM MgCl and 5 mM HEPES (pH adjusted to 7.4 with NaOH). A 
voltage ramp protocol from −80 mV to 80 mV over 400 ms was repeated every second during 
the follow- ing conditions: while the cell was dialyzed by the pipette, followed by at least 60 s 
of illumination with 405-nm light, after which optovin (10 µM) containing extracellular solution 
was perfused into the bath, followed by 1 min of illumination. Current elicited at holding 
potentials of 70 mV as well as the slope of the current-voltage relation while ramping from 0 to 
70 mV were used to characterize TRPA1 activation."
NIMH PDSP profiling "
Activity determinations were generously provided by the National Institute of Mental Health’s 
Psychoactive Drug Screening Program, contract no. HHSN-271-2008-00025-C (NIMH PDSP). 
Complete assay details are found online at http://pdsp.med.unc.edu/UNC-CH%20 Protocol
%20Book.pdf."
Calcium imaging methods. "
C57Bl/6 male mice (3–4 weeks old) were decapitated, and DRG were dissected into 4°C 
Hank’s Balanced Salt Solution (HBSS; Gibco), then neurons were dissociated using 
collagenase (1 mg/mL; Worthington) and dispase (5 mg/mL; Gibco) dissolved in HBSS. 
Neurons were plated in Neurobasal-A medium (Invitrogen), supplemented with B-27 
Supplement (Gibco), L-glutamine (Gibco) and penicillin-streptomycin (Gibco). The neurons 
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were plated onto coverslips coated with 0.1 mg/mL poly-D-lysine (Sigma) and 5 g/mL laminin 
(Sigma). After 24 h, neurons were washed with assay buffer (HBSS, supplemented with 9 mM 
HEPES, 11 mM D-glucose, 0.1% fatty-acid free BSA, pH 7.3) and incubated for 1 h with 2 µM 
Fura2-AM (Invitrogen) with 0.2% pluronic (Invitrogen) in assay buffer in the dark at room 
temperature. The neurons were then washed with assay buffer and allowed to equilibrate at 
room temperature for 30 min before imaging. After a 120-s baseline perfusion of assay buffer 
containing 3.3% DMSO, 100 µM optovin dissolved in the DMSO-assay buffer solution or the 
DMSO-assay buffer solution alone as a control was perfused onto the neurons for a period of 
1 min. Fura-2 is activated with UV light, and the process of imaging Fura-2 was enough to 
activate the optovin. As a no-light control to ensure that the presence of optovin alone did not 
cause activation, imaging was stopped for the 1-min period of optovin treatment and resumed 
once the solution per- fused back onto the neurons. Following this 1-min period, cells were 
perfused with DMSO-assay buffer to remove the agonist, which was followed by addition of 
100 µM mustard oil (in DMSO assay buffer) to determine the total number of TrpA1-
expressing neurons present. Images were acquired on a Nikon Eclipse Ti microscope (Nikon, 
Melville, NY). Neurons were counted as activated if they showed a response during the 1-min 
activation period. All procedures involving animals for calcium imaging were approved by the 
Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill."
HEK293 cells were plated onto polylysine-coated glass-bottom culture dishes (MatTek Corp) 
and grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) supplemented with 10% 
FBS and 100 U/mL penicillin and 100 g/ml streptomycin. After 24 h, cells were transfected, 
according to man- ufacturer’s instructions, in Opti-MEM medium, using 4 µl Lipofectamine 
2000 (Invitrogen), 0.5 g EGFP in pcDNA and 0.3 g TrpA1 DNA per dish. Medium was replaced 
after 2 h, and cells were cultured for an additional 17 h. As previously described for neurons, 
 74
HEK cells were washed with assay buffer (HBSS Gibco 14025, supplemented with 9 mM 
HEPES, 11 mM D-glucose, 0.1% fatty acid–free BSA, pH 7.3) and incubated for 1 h with 2 µM 
Fura2-AM (Invitrogen) with 0.2% pluronic (Invitrogen) in assay buffer in the dark at room 
temperature. The cells were then washed with assay buffer and allowed to equilibrate at room 
temperature for 30 min before imaging. At the start of the imaging session for each dish, cells 
were replaced with DMSO assay buffer. After 50 s of imaging, assay buffer was aspirated by 
hand and replaced with 100 M optovin dissolved in the DMSO assay buffer solution. Each dish 
of HEK cells was imaged for a total of 3 min."
Cells were transfected with the hTRPA1 (ref. 38), TRPA1C621S (ref. 38), hTRPA1C633S (ref. 
39) and hTRPA1C633S C856S (ref. 39) plasmids as described."
Long-term toxicity testing!
To determine the long-term effects of optovin exposure on development, behavior and 
survival, we analyzed the development, behavior and survival of larvae (n = 150) and adult 
zebrafish (n = 2) exposed to optovin (10 µM) for 96 h. We did not identify any differences 
between the appearance, touch response, heart rate, fin movements or morphology between 
the treated and untreated groups."
NIMH PDSP in vitro receptor profiling!
In vitro receptor profiling was performed by the National Institute of Mental Health’s 
Psychoactive Drug Screening Program, contract no. HHSN-271-2008-00025-C (NIMH PDSP). 
For primary screening, data represent mean percentage inhibition at the receptor subtypes (n 
= 4 determinations; Supplementary Table 1). The default primary screening concentration is 
10 µM. If >50% inhibition was obtained in the primary screen, Ki determinations were 
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performed at concentrations ranging from 10 pM to 10 µM. For Ki determinations, data 
represent Ki (nM) values obtained from nonlinear regression. Complete assay details are 
found online at http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf."
Dissection and culture!
Male adult C57Bl/6 mice were purchased from Jackson Laboratories and housed in the animal 
facilities of Children’s Hospital Boston on a 12-h alternating light-dark cycle. Animals for 
imaging were dissected after 7 weeks of age. TRPA1-KO mice were provided by K. Kwan 
(Howard Hughes Medical Institute, Harvard Medical School)11. After CO2 asphyxiation and 
cervical translocation and following spinal laminectomy, the left and right DRG from the whole 
spine were removed and placed in 4 °C Hank’s buffered saline solution without calcium and 
magnesium (HBSS, Life Technologies). After the DRG were collected and spun down for 3 
min at 1,000 r.p.m. (150 g), they were placed in a collagenase/dispase solution (3 mg/mL 
dispase II and 1 mg/mL collagenase A, Roche Applied Science) and allowed to incubate at 37 
°C for 90 min. After incubation, the cells were washed in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Life Technologies), fortified with 4.5 g L/D- glucose, L-glutamine, 110 mg/L sodium 
pyruvate, 10% FBS (Life Technologies), penicillin (500 U/mL, Cellgro) and streptomycin (500 
g/mL, Cellgro). DNAse (125 U/mL, Sigma) was then added, and the solution was triturated 
using successively smaller caliber flame-polished Pasteur pipettes. This solution was gently 
layered onto a bovine serum albumin gradient (10% albumin from bovine serum, Sigma in 
PBS, Life Technologies) and spun at 150 g for 12 min. After removal of the supernatant, the 
cells were washed again in DMEM; suspended in neurobasal medium (Life Technologies) 
supplemented with L-glutamine (20 mM, Life Technologies), B-27 supplement (Life 
Technologies), penicil- lin (500 U/mL, Cellgro) and streptomycin (500 g/mL, Cellgro); plated 
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onto laminin-treated (1 mg/mL, Sigma) 15-mm glass-bottom dishes (MatTek Corporation); and 
then placed in an incubator at 37 °C (5% CO2) overnight. All imaging was performed 1 d after 
dissection and culture."
Calcium imaging!
DRG neurons were imaged on a Nikon Ti Eclipse inverted microscope. Fura-2, AM (Life 
Technologies) was loaded into the neurons for 30 min (room temperature, 4 µg/mL). After 
washing with standard extracellular solution (Boston BioProducts), the cells were imaged 
using a QImaging EXi Aqua cooled camera, and data were collected and analyzed using NIS 
Elements software (AR 3.10). Neurons were selectively exposed to various solutions via a 
gravity-assisted perfusion system. Responses were included if they were 20% greater than 
the baseline."
Mouse behavior "
Male adult C57Bl/6 mice were assessed for behavior after 7 weeks of age, purchased from 
Jackson Laboratories and housed in the animal facilities of Children’s Hospital Boston on a 
12-h alternating light-dark cycle, with food and water provided ad libitum. This behavioral 
protocol was approved by the Institutional Animal Care and Use Committee at Children’s 
Hospital Boston. After habituation periods in a custom-built behavior chamber, mice were 
either treated with 20 uL of optovin solution (15 mM in DMSO, Sigma-Aldrich) or vehicle 
control (DMSO) on the ear. Upon return to the behavior chamber, a laser (405 nm, class 3A, 
common laser pointer) was trained on the treated ear. Time to activation of a characteristic 
head-twitch or head-shake response (HSR) was recorded for each animal over five separate 
trials47. The response is a rapid, radial twitch of the head about the dorsal-ventral axis of the 
head. The time cutoff for laser stimulation was set at 60 s if no response was elicited (four 
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optovin versus four control animals). One optovin-treated mouse was excluded from the mean 
analysis because of extreme nonresponsiveness. Average time to response per animal was 
calculated by a blinded coder using VLC media playback at 0.25× speed who measured the 
actual time the laser was on the ear. Data were pooled between animals within groups. Error 
bars represent standard error."
"
Works Cited!
1."Alexander, G.M. et al. Remote control of neuronal activity in transgenic mice expressing 
evolved G protein–coupled receptors. Neuron 63, 27–39 (2009). "
2."Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S. & Roth, B.L. Evolving the lock to fit the 
key to create a family of G protein–coupled receptors potently activated by an inert 
ligand. Proc. Natl. Acad. Sci. USA 104, 5163–5168 (2007). "
3."Banghart, M., Borges, K., Isacoff, E., Trauner, D. & Kramer, R. Light-activated ion channels 
for remote control of neuronal firing. Nat. Neurosci. 7, 1381–1386 (2004). "
4."Boyden, E.S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond- timescale, 
genetically targeted optical control of neural activity. Nat. Neurosci. 8, 1263–1268 
(2005). "
5."Deisseroth, K. Optogenetics. Nat. Methods 8, 26–29 (2011). "
6."Ferguson, S.M. et al. Transient neuronal inhibition reveals opposing roles of indirect and 
direct pathways in sensitization. Nat. Neurosci. 14, 22–24  
(2011). "
7."Szobota, S. et al. Remote control of neuronal activity with a light-gated glutamate receptor. 
Neuron 54, 535–545 (2007). "
8."Janovjak, H., Szobota, S., Wyart, C., Trauner, D. & Isacoff, E. A light-gated, potassium-
selective glutamate receptor for the optical inhibition of neuronal  
firing. Nat. Neurosci. 13, 1027–1032 (2010). "
9."Volgraf, M. et al. Reversibly caged glutamate: a photochromic agonist of ionotropic 
glutamate receptors. J. Am. Chem. Soc. 129, 260–261 (2007). "
10. Wang, S. et al. All optical interface for parallel, remote, and spatiotemporal control of 
neuronal activity. Nano Lett. 7, 3859–3863 (2007). "
 78
11. Kwan, K.Y. et al. TRPA1 contributes to cold, mechanical, and chemical nociception but is 
not essential for hair-cell transduction. Neuron 50, 277–289  
(2006). "
12. Kramer, R.H., Fortin, D.L. & Trauner, D. New photochemical tools for controlling neuronal 
activity. Curr. Opin. Neurobiol. 19, 544–552 (2009). "
13. Callaway, E.M. & Katz, L.C. Photostimulation using caged glutamate reveals functional 
" circuitry in living brain slices. Proc. Natl. Acad. Sci. USA 90, 7661–7665 (1993)."
14. Dalva, M.B. & Katz, L.C. Rearrangements of synaptic connections in visual cortex "
" revealed by laser photostimulation. Science 265, 255–258 (1994)."
15. Fortin, D.L. et al. Photochemical control of endogenous ion channels and cellular "
" excitability. Nat. Methods 5, 331–338 10.1038/nmeth.1187 (2008)."
16. Fortin, D.L. et al. Optogenetic photochemical control of designer K+ channels in "
" mammalian neurons. J. Neurophysiol. 106, 488–496 (2011)."
17. Noguchi, J. et al. In vivo two-photon uncaging of glutamate revealing the structure-function 
" relationships of dendritic spines in the neocortex of adult mice. J. Physiol. (Lond.) 589, 
" 2447–2457 (2011)."
18. Volgraf, M. et al. Allosteric control of an ionotropic glutamate receptor with an optical "
" switch. Nat. Chem. Biol. 2, 47–52 (2006)."
19. Wieboldt, R. et al. Photolabile precursors of glutamate: synthesis, photochemical "
" properties, and activation of glutamate receptors on a microsecond time scale. Proc. 
" Natl. Acad. Sci. USA 91, 8752–8756 (1994)."
20. Mourot, A. et al. Rapid optical control of nociception with an ion-channel photoswitch. Nat. 
" Methods 9, 396–402 (2012)."
21. Brain, S.D. TRPV1 and TRPA1 channels in inflammatory pain: elucidating mechanisms. 
" Ann. NY Acad. Sci. 1245, 36–37 (2011)."
22. Jordt, S.E. & Ehrlich, B.E. TRP channels in disease. Subcell. Biochem. 45, 253–271 "
" (2007)."
23. Kremeyer, B. et al. A gain-of-function mutation in TRPA1 causes familial episodic pain 
" syndrome. Neuron 66, 671–680 (2010)."
24. Schwartz, E.S. et al. Synergistic role of TRPV1 and TRPA1 in pancreatic pain and "
" inflammation. Gastroenterology 140, 1283–1291 (2011)."
25. MacRae, C.A. & Peterson, R.T. Zebrafish-based small molecule discovery. Chem. Biol. 10, 
" 901–908 (2003)."
26. Zon, L.I. & Peterson, R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4, 
" 35–44 (2005)."
 79
28. Schmitt, E.A. & Dowling, J.E. Early retinal development in the zebrafish, Danio rerio: light 
" and electron microscopic analyses. J. Comp. Neurol. 404, 515–536 (1999)."
30. Dhaka, A., Viswanath, V. & Patapoutian, A. TRP ion channels and temperature sensation. 
" Annu. Rev. Neurosci. 29, 135–161 (2006)."
31. Bandell, M. et al. Noxious cold ion channel TRPA1 is activated by pungent compounds 
" and bradykinin. Neuron 41, 849–857 (2004)."
32. Moran, M.M., Xu, H. & Clapham, D.E. TRP ion channels in the nervous system. Curr. 
" Opin. Neurobiol. 14, 362–369 (2004)."
33. Escalera, J., von Hehn, C.A., Bessac, B.F., Sivula, M. & Jordt, S.E. TRPA1 mediates the 
" noxious effects of natural sesquiterpene deterrents. J. Biol. Chem. 283, 24136–24144 
" (2008)."
34. Prober, D.A. et al. Zebrafish TRPA1 channels are required for chemosensation but not for 
" thermosensation or mechanosensory hair cell function. J. Neurosci. 28, 10102–10110 
" (2008)."
35. Eid, S.R. et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and 
" neuropathy-induced mechanical hypersensitivity. Mol. Pain 4, 48 (2008)."
36. Laustriat, G. Molecular mechanisms of photosensitization. Biochimie 68, 771–778 (1986)."
37. Ouannes, C. & Wilson, T. Quenching of singlet oxygen by tertiary aliphatic amines. Effect 
" of DABCO (1,4-diazabicyclo [2.2.2]octane). J. Am. Chem. Soc. 90, 6527–6528 (1968)."
38. Macpherson, L.J. et al. Noxious compounds activate TRPA1 ion channels through "
" covalent modification of cysteines. Nature 445, 541–545 (2007)."
39. Takahashi, N. et al. TRPA1 underlies a sensing mechanism for O2. Nat. Chem. Biol. 7, 
" 701–711 (2011)."
40. Hinman, A., Chuang, H.H., Bautista, D.M. & Julius, D. TRP channel activation by "
" reversible covalent modification. Proc. Natl. Acad. Sci. USA 103, 19564–19568 (2006)."
43. Patch, R.J. et al. Identification of diaryl ether–based ligands for estrogen- related receptor 
" alpha as potential antidiabetic agents. J. Med. Chem. 54, 788–808 (2011)."
44. Serafimova, I.M. et al. Reversible targeting of noncatalytic cysteines with chemically tuned 
" electrophiles. Nat. Chem. Biol. 8, 471–476 (2012)."
45. Herrou, J. & Crosson, S. Function, structure and mechanism of bacterial photosensory 
" LOV proteins. Nat. Rev. Microbiol. 9, 713–723 (2011)." "
47. Corne, S.J., Pickering, R.W. & Warner, B.T. A method for assessing the effects of drugs on 
the central actions of 5-hydroxytryptamine. Br. J. Pharmacol. Chemother. 20, 106–120 
(1963). 
 80
Chapter 5: Activity-dependent silencing reveals functionally distinct itch-generating 
sensory neurons* **!56
"
ABSTRACT"
The peripheral terminals of primary sensory neurons detect histamine and non-histamine itch-
provoking ligands through molecularly distinct transduction mechanisms. It remains unclear, 
however, whether these distinct pruritogens activate the same or different afferent fibers. 
Using a strategy of reversibly silencing specific subsets of murine pruritogen-sensitive sensory 
axons by targeted delivery of a charged sodium-channel blocker, we found that functional 
blockade of histamine itch did not affect the itch evoked by chloroquine or SLIGRL-NH2, and 
vice versa. Notably, blocking itch-generating fibers did not reduce pain-associated behavior. 
However, silencing TRPV1+ or TRPA1+ neurons allowed allyl isothiocyanate or capsaicin, 
respectively, to evoke itch, implying that certain peripheral afferents may normally indirectly 
inhibit algogens from eliciting itch. These findings support the presence of functionally distinct 
sets of itch-generating neurons and suggest that targeted silencing of activated sensory fibers 
may represent a clinically useful anti-pruritic therapeutic approach for histaminergic and non- 
histaminergic pruritus."
INTRODUCTION"
* The behavior work was performed by David Roberson in the Woolf laboratory. I performed calcium 
imaging experiments showing the population connections between TRPV1/histamine and TRPA1/
chloroquine after dissecting and culturing DRG neurons, demonstrating an anatomical distinction 
between the histamine-independent and dependent itch neurons in trigeminal neurons.
** This chapter is a modified version of an article previously published as: Roberson, D. P., Gudes, S., 
Sprague, J. M., Patoski, Haley A. W., Robson, V. K., Blasl, F., Duan, B., Oh, S. B., Bean, B. P., Ma, Q., 
Binshtok, A. M., & Woolf, C. J. Activity-dependent silencing reveals functionally distinct itch-generating 
sensory neurons. Nat. Neurosci. 16, 910–8 (2013).
Itch is a complex unpleasant cutaneous sensation that in some respects resembles pain, yet 
is different in terms of its intrinsic sensory quality and the urge to scratch. Histamine-mediated 
itch, as in patients with urticaria, can be effectively treated using histamine receptor 
antagonists1. However, itch accompanying most chronic pruritic diseases, including atopic 
dermatitis (eczema)2, allergic itch3 and dry skin itch4, is not predominantly mediated by 
histamine5. The G protein–coupled receptors responsive to specific itch-generating ligands are 
distinct, although, at a cellular level, there is overlapping responsiveness of trigeminal and 
dorsal root ganglia (DRG) neurons to itch-producing pruritogens and pain-producing 
algogens6–9. Histamine-sensitive H1 receptors (H1Rs) generate histamine itch and are 
expressed by TRPV1+ phospholipase-β3 (PLCβ3)+ fibers10,11. Itch evoked by chloroquine is 
mediated by Mas-related G protein–coupled receptor (Mrgpr) A3 (refs. 6,12), whereas 
MrgprC11 is sensitized in dry skin itch9,13 and activated by pruritogens released from mast 
cells during allergic itch3. Notably, co-activation of TRPV1 and H1R is required to produce 
histamine itch14, whereas MrgprA3- or MrgprC11-mediated itch requires co-activation of 
TRPA112, even though each of these TRP channels are canonical nociceptor transducers. In 
vitro calcium-imaging experiments have shown that neurons expressing MrgprA3 also 
respond to histamine, which has been interpreted as indicating a single neuronal path for 
histaminergic and MrgprA3- dependent itch6. Supporting this, ablation of neurons expressing 
MrgprA3 reduces the scratching evoked by histamine, chloroquine, dry skin and allergic 
inflammation15. However, others report separate neural pathways mediating histamine and 
certain types of non-histamine itch16,17. Furthermore, although primary sensory neurons of 
juvenile mice respond to multiple itch mediators, this nonspecificity decreases with age18. 
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Thus, it remains controversial whether there are separate afferents in the adult that mediate 
histamine itch and MrgprA3-dependent non-histamine itch. This distinction is clinically 
important, as therapies targeting histaminergic itch fibers might be ineffective for treating non-
histaminergic itch if the neurons mediating the two itches are functionally distinct in the adult."
To study whether histaminergic and non-histaminergic itch are functionally distinct, we 
adapted a method originally designed for achieving a pain-specific peripheral nerve block19,20 
to selectively silence the peripheral terminals of different subsets of pruritogen- and algogen-
responsive primary afferents in an activity-dependent manner. To do this, we targeted the 
charged, membrane-impermeable lidocaine derivative N-ethyl-lidocaine (QX-314, a sodium 
channel blocker) through large pore ion channels activated specifically by different algogens 
and pruritogens."
"
METHODS"
Cell culture. Trigeminal neuron cultures were prepared from adult (2–3 month old) CD-1 
mice44. In short, trigeminal neurons were removed and placed into Hank’s balanced salt 
solution and 1% penicillin-streptomycin (vol/vol, Sigma), then digested in 5 mg ml−1 
collagenase and 1 mg ml−1 Dispase II (Roche). Cells were triturated in the presence of 
DNAse I inhibitor (50U) and centrifuged through 10% BSA (vol/vol, Sigma). The cell pellet was 
resuspended in 1 ml Neurobasal (Sigma) containing B27 supplement (Invitrogen), penicillin 
and streptomycin (Sigma), 10 µM AraC. Cells were plated onto poly-d-lysine–coated (500 µg 
ml−1) and laminin-coated (5 mg ml−1) 35-mm tissue culture dishes (Becton Dickinson) at 
8,000–9,000 per dish, at 37 °C, in 5% carbon dioxide."
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Calcium imaging experiments. All dissections were performed on adult (2–4 month old) 
male CD-1 mice. The calcium-indicator dye Fura-2 a.m. was introduced at 2 µg ml−1 for 30 
min at 22±2 °C, washed and analyzed on a Nikon Eclipse Ti inverted microscope with exi-
aqua CCD camera and NIS-elements AR 3.10 software. Each cell was given 3 min to recover 
from each pruritogen exposure and 8 min to recover between exposure to AITC and capsaicin. 
Each exposure lasted for 60 s, except for capsaicin, which was exposed for 10 s. Pruritogens 
were locally applied, with the perfusion opening placed approximately 150 µm from the field of 
view, and preliminary exposure to standard extracellular solution was employed before 
exposure to reagents made in SES. Pruritogen order was assigned at random (coin toss) for 
each plate, and no order effects were observed between differently ordered groups."
Behavioral studies. All animal procedures were approved by the Boston Children’s Hospital 
Animal Care and Use Committee. Naive adult (2–4 month old) male CD-1 mice (Charles River 
Laboratories) housed in groups of five mice using a normal 12-h light/dark cycle were used. 
Mice were fully habituated to handling before all experimental procedures and were randomly 
assigned to experimental groups. The day before beginning itch experiments, mice were 
briefly anesthetized by inhalation of 1–2% isofluorane (vol/vol) and a ~1-cm2 area of hair was 
shaved on the right cheek of each mouse. Capsaicin (Sigma-Aldrich) was freshly prepared by 
dilution in vehicle (20% ethanol (vol/vol), 5% Tween 20 (vol/vol), in saline, 10 ml). All other 
drug solutions were prepared fresh in normal saline (0.9% NaCl, wt/vol)."
Itch assay. Mice received intradermal microinjections of pruritogen, algogen, QX-314, vehicle 
or a combination of pruritogen or algogen together with QX-314 intradermally in the cheek. To 
ensure proper intradermal injection, needle puncture with a 28-gauge needle was initiated 
bevel-up at 5° to the plane of taut skin until initial penetration, then inserted horizontally until 
the needle tip was 0.5 cm beyond the point of insertion before intradermal evacuation of 
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syringe contents. Correct injection was confirmed by presence of a slightly domed bulla 
immediately following removal of needle. For sequential injection experiments, the intradermal 
bullae of the conditioning (first) injection were outlined with fine-tip permanent marker to 
denote the extent of intradermal drug distribution, thereby providing visible drug distribution 
boundaries for subsequent injections. Mice not receiving proper drug injections were noted 
and excluded from the study before observation. Immediately after conditioning injection, mice 
were placed in a custom-built itch observation apparatus and video recorded during the 
mouse dark cycle as previously described26. Scratches and/or wipes were subsequently 
quantified by blinded observers."
Statistical analysis. Sample sizes for all experiments were chosen according to standard 
practice in the field. For electrophysiological experiments, the significance of the effect was 
calculated using two-way ANOVA non-parametric test followed by Bonferroni post-test. 
Comparison of group means for behavior studies was performed using Student’s t test. All bar 
graphs are plotted as mean s.e.m. For behavioral studies, n represents the total number of 
mice used in each group."
"
RESULTS"
Selective silencing of pruriceptors in vivo 
To determine whether we could selectively silence pruriceptors in vivo, we used intradermal 
cheek injections of pruritogens and QX- 314, and then characterized pruriceptor function by 
quantifying ensuing behavioral responses related to itch (hindlimb scratching of cheek) or pain 
(forelimb wiping of cheek)26. Intradermal injection of histamine (100 µg per 20 µl) produced 
scratching (64.3 ± 7.5 bouts, n = 6 mice) that fully resolved in 30 min. There was no significant 
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Figure 5.1 - Co-administration of QX-314 and pruritogens inhibits subsequent pruritogen-evoked 
scratching. (a,c,e) Sequential pruritogen cheek injections at 30-min inter-stimulus intervals evoked similar 
levels of cheek scratching (itch) bouts. (b,d,f) Pruritogen-evoked scratching was inhibited 30-min after 
conditioning injection of pruritogen and 1% QX-314. (a) Conditioning injection: histamine (100 µg per 20 
µl), total scratching bouts in 30 min (TSB) = 64.3±7.5 bouts. Test injection: histamine (100 µg per 10 l), 
TSB = 49.2±9.7, P > 0.05, n = 6 mice, degrees of freedom (df) = 10. (b) Conditioning injection: histamine 
(100 µg per 20 µl) + 1% QX-314, TSB = 56.0±8.3. Test injection: histamine (100 µg per 10 µl), TSB = 
7.5±3.8, P < 0.001, n = 6 mice, df = 10. (c) Conditioning injection: chloroquine (50 µg per 20 µl), TSB min = 
103.0±19.1. Test injection: chloroquine (50 µg per 10 µl), TSB = 109.0±20.8, P > 0.05, n = 7 mice, df = 12. 
(d) Conditioning injection: chloroquine (50 µg per 20 µl) + 1% QX-314, TSB = 110.0±13.7. Test injection: 
chloroquine (50 µg per 10 µl), TSB = 31.8±13.3, P < 0.01, n = 6 mice, df = 10. Data are presented as mean 
s.e.m. of total scratching bouts per minute for 30 min after conditioning injection and test injection. P values 
represent comparison of value of mean total scratching bouts in 30 min evoked by test injection to those 
evoked by conditioning injection."
change in scratching (56.0 ± 8.3 bouts, n = 6 mice, P > 0.05) when histamine was injected 
with 1% QX-314. On the basis of the delayed time course of nociceptor block in vivo in 
response to a combination of capsaicin and QX-314 (ref. 19), and considering the gradual 
development of full sodium current block in vitro after QX-314 and histamine co-administration 
(data not shown), we hypothesized that the short duration of histamine-evoked scratching 
behavior (~25 min) was too brief to detect the slow-onset blocking effects generated by co-
administration of histamine with QX-314. To test this, we devised a behavioral model using 
two sequential intradermal injections, 30 min apart, of a pruritogen into the same intradermal 
cheek injection site. Identical pruritogen doses were used in each injection. Only behavior 
evoked by the test (second) injection was compared with behavior evoked by other identical 
test injections, with the experimental variable being the identity of the conditioning (first) 
injection given 30 min earlier."
When histamine alone was given for the conditioning injection (100 µg per 20 µl) and again 30 
min later for the test injection (100 µg per 10 µl) at the same site, the amount of scratching 
evoked by the two injections was not significantly different (P > 0.05; Figure 5.1a). However, 
histamine-evoked scratching was effectively abolished 30 min after a conditioning injection of 
both histamine and QX-314 (Figure 5.1b), but not when it was preceded by an injection of 
QX-314 alone (Figure 5.2a). We conclude that histamine-mediated activation of large pore 
channels, such as TRPV1 (ref. 14), permitted uptake of QX-314 and produced a slow (<30 
min) onset electrical silencing of the histamine-responsive sensory fibers, which then blocked 
the response to subsequent injection of histamine (Figure 5.1b)."
We further hypothesized that intradermal administration of chloroquine with QX-314 could 
block chloroquine itch by permitting selective uptake of QX-314 through chloroquine-mediated 
activation of a large-pore ion channel, likely TRPA1 (ref. 12). Co-injection of QX-314 together 
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with chloroquine (50 µg per 20 µl) inhibited scratching produced by subsequent chloroquine 
(50 µg per 10 µl) test injection, whereas injection of chloroquine alone or QX-314 alone did not 
(Figure 5.1c,d and Figure 5.2b). We conclude that large-pore channels downstream of 
chloroquine-evoked MrgprA3 activation, possibly TRPA1 (ref. 12), permit selective uptake of 
QX-314 and subsequent electrical silencing of chloroquine-sensitive afferent fibers."
Distinct fibers mediate histamine and non-histamine itch"
We next used the silencing strategy to reveal whether different pruritogens activate the same 
or unique peripheral afferent pathways by administering test injections (10 µl) of histamine 
(100 µg) or chloroquine (50 µg) 30 min after conditioning injections (20 µl) of histamine (100 
µg), chloroquine (50 µg) or SLIGRL (50 µg) with or without QX-314. We hypothesized that if 
histaminergic and non-histaminergic itch are transmitted by different subsets of afferent fibers, 
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Figure 5.2 - Pruritogen and algogen- mediated scratching measured 30 minutes after conditioning 
injections (indicated at the x-axes). (a) Histamine-evoked hindlimb scratching bouts. (b) Chloroquine-
evoked hindlimb scratching bouts. P-value annotations represent comparison of value of annotated 
column to vehicle conditioning injection value (No annotation, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 
0.001). Error bars represent SEM."
application of both histamine and QX-314 will block histaminergic itch, whereas chloroquine 
itch will remain intact, and vice versa."
We first examined whether histamine-evoked scratching is affected by the targeted silencing 
of chloroquine-activated pruriceptors. Histamine-evoked scratching was unchanged 30 min 
after a conditioning injection of both chloroquine and QX-314 (Figure 5.3a), even though this 
treatment blocked subsequent chloroquine itch (Figures 5.1b and 5.3b). Similarly, 
conditioning injection of SLIGRL and QX-314 (which reverses later SLIGRL-evoked 
scratching) did not reduce subsequent histamine (100 µg per 10 µl) itch (Figure 5.3a)."
We then asked whether chloroquine itch is affected following silencing of histamine- or 
SLIGRL-sensitive itch fibers by injecting chloroquine 30 min after administration of QX-314 
and either histamine or SLIGRL. Chloroquine-evoked itch was blocked after co-injection of 
SLIGRL and QX-314, but not by co-administration of histamine and QX-314 (Figure 5.3b)."
It appears that a common afferent population mediates chloroquine and SLIGRL itch, but this 
population is functionally distinct from the neurons responsible for histamine itch. These 
findings contrast, however, with prior in vitro data showing that all chloroquine-responsive 
DRG neurons respond to histamine6. A possible explanation for this discrepancy is that 
peripheral terminals of trigeminal neurons differ from DRG neuron cell bodies in terms of their 
responsiveness to multiple pruritogens. To explore this, we repeated the same silencing 
strategy on the back below the neck. Treatment with both histamine and QX-314 did not 
reduce subsequent chloroquine-evoked scratching when compared with treatment with 
vehicle, whereas intradermal injection of both chloroquine and QX-314 inhibited subsequent 
chloroquine-evoked scratching (data not shown), indicating that facial and somatic itch appear 
to be similar in terms of the functional independence of histamine and non-histamine itch."
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Another possibility is that different pruriceptor subsets exist with high or low sensitivity to either 
histamine or non-histamine pruritogens. To investigate this, we varied the dose of pruritogen 
given with 1% QX-314 (20 µl) for conditioning injections. Application of a lower dose of 
histamine (10 µg) together with QX-314 inhibited subsequent histamine-evoked scratching 
without reversing chloroquine (50 µg) scratching (Figure 5.3a,b), which was essentially the 
same as the observed effects following a higher dose of histamine (100 µg) with QX-314. 
However, increasing the concentration of histamine to 108.7 mM (400 µg per 20 µl) with 
QX-314 for conditioning injections blocked scratching evoked by both histamine and 
chloroquine (Figure 5.3a,b), indicating that an overlap manifests only at very high doses of 
histamine. Higher doses of chloroquine (200 or 400 µg) and QX-314 blocked later chloroquine 
itch behavior, but not scratching evoked by histamine. However, using 96.9 mM chloroquine (1 
mg per 20 µl) together with QX-314 for conditioning injections blocked subsequent histamine- 
and chloroquine-evoked scratching (Figure 5.3a,b). These data suggest that histamine and 
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Figure 5.3 - Distinct primary afferents mediate histaminergic itch and non-histaminergic itch. Pruritogen-
evoked cheek scratching (itch) bouts 30 min after different conditioning injections, indicated at the x 
axes, are shown. (a–c) Intradermal test injection of histamine (100 µg per 10 µl) alone (a), or 
chloroquine (CQ, 50 µg per 10 µl) alone (b) Error bars represent s.e.m. (n = 5–7 mice for all groups).
chloroquine generally activate functionally distinct pruriceptor populations, but these fibers can 
respond to multiple pruritogens, either directly or indirectly, when they are presented at very 
high, presumably non-physiological29,30, concentrations (histamine, 107.8 mM; chloroquine, 
96.9 mM)."
Histamine and chloroquine act on different sets of neurons"
The responsiveness of DRG neurons to multiple pruritogens decreases with age18. In juvenile 
mice, 60–100% of all chloroquine-responsive DRG cells also respond to histamine6,18, 
whereas only half of chloroquine-responsive DRG neurons respond to histamine in adolescent 
mice18. We asked whether distinct chloroquine- and histamine- sensitive neuronal populations 
could be revealed in adult (2–4 months old) mice by their sensitivity to pruritogens in vitro. 
MrgprA3 receptors are activated by 10 µM chloroquine and maximally activated by 1 mM 
chloroquine in HEK293 cells6. Murine DRG neurons respond to histamine at doses as low as 
10 µM14. We examined coincident calcium responses of 564 cultured trigeminal neurons to 10 
µM histamine and 10 µM chloroquine. Histamine activated 4.1% (23 of 564) of trigeminal 
neurons, whereas 3.0% (17 of 564) responded to chloroquine (Figure 5.4a). A majority of 
chloroquine- and histamine- responding trigeminal neurons responded to only one pruritogen. 
Among chloroquine-activated cells, 76.5% (13 of 17) responded to chloroquine, but not to 
histamine, whereas the remaining 23.5% (4 of 17) responded to both 10 µM histamine and 10 
µM chloroquine. Likewise, trigeminal neurons responding to histamine were largely 
unresponsive to chloroquine: 82.6% (19 of 23) responded to histamine, but not chloroquine, 
and 17.4% (4 of 23) responded to both histamine and chloroquine."
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To determine whether responsiveness of adult trigeminal neurons to chloroquine or histamine 
is dependent on pruritogen dose, we further explored coincident calcium responses to 100 µM 
histamine and 100 µM chloroquine. Most trigeminal neurons that responded to either 100 µM 
histamine (4.8% of all cells) or 100 µM chloroquine (4.3% of all cells) did not respond to both 
(0.9% of all cells) (Figure 5.5a). Moreover, we also found that the populations of fibers 
responding to chloroquine and histamine in DRG neurons from adult mice were, as in the 
trigeminal ganglia, largely distinct (Figure 5.5b). These data indicate that primary afferent 
populations responding to histamine and chloroquine are largely distinct in adult mice."
The requisite expression of TRPV1 for histaminergic itch14 and TRPA1 for chloroquine-evoked 
itch12 raises the question of whether relative expression patterns of TRPA1 and TRPV1 differ 
among chloroquine- and histamine-sensitive neuronal populations. To answer this, we 
exposed cultured trigeminal neurons to 100 µM AITC and 1 µM capsaicin and measured the 
coincident responses of neurons to both agents. Consistent with the described receptor 
expression patterns for neurons that mediate histamine itch (for example, H1R and 
TRPV1)10,14 and chloroquine itch (for example, MrgprA3 and TRPA1)6,12, we found that a 
majority (16 of 23, 69.6%) of histamine- responsive cells responded to capsaicin (Figure 5.4b) 
and most (9 of 17, 52.9%) of the chloroquine-activated neurons were sensitive to AITC 
(Figure 5.4c). The inverse relationships were also true; most (14 of 23 neurons, 60.8%) 
histamine-responsive trigeminal cells did not respond to AITC (Figure 5.4d), and capsaicin 
failed to activate a majority (12 of 17, 70.6%) of chloroquine-activated neurons (Figure 5.4e)."
Roles of TRP channels in histamine and non-histamine itch"
The different expression patterns of TRPV1 and TRPA1 among histamine- and chloroquine-
sensitive neurons in vitro (Figure 5.4) suggest that targeted silencing of TRPV1 or TRPA1 
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fibers may differently affect histamine itch and chloroquine itch. To explore this, we 
administered 20-µl conditioning injections of capsaicin (0.1%) or AITC (0.15%), with or without 
QX-314, and then administered 10-µl test injections of the pruritogens histamine (100 µg), 
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Figure 5.4 - Proportional representation of coincident trigeminal cell responses to low-dose 
chloroquine and histamine and their overlapping responsiveness with capsaicin and AITC. 
Shown are Venn diagrams of calcium responses of 564 cultured trigeminal neurons to 10 µM 
histamine, 10 µM chloroquine, 1 µM capsaicin and 100 µM AITC. (a) Histamine (10 µM) activated 
23 of 564 trigeminal neurons, whereas 17 neurons responded to 10 µM chloroquine. Among 
histamine-activated cells, 19 of 23 responded to histamine, but not chloroquine, and 4 of 23 
responded to both histamine and chloroquine. For trigeminal cells responding to chloroquine, 13 
of 17 responded to chloroquine, but not histamine. (b) Capsaicin activated 235 of 564 cells. 
Among the histamine-responsive cells, 16 of 23 also responded to capsaicin. (c) AITC activated 
161 of 564 trigeminal neurons, and more than half of chloroquine-responding cells (9 of 17) 
responded to AITC. (d) AITC activated 9 of 23 of histamine-responding cells. (e) Capsaicin 
chloroquine (50 µg) or SLIGRL (50 µg) 30 min later at the same site. Injection of capsaicin 
alone did not significantly reduce histamine- or chloroquine- evoked scratching (P > 0.05; 
Figure 5.2). However, when the conditioning injection of capsaicin was administered together 
with QX-314, the scratching evoked by subsequent histamine injection was abolished (Figure 
5.6a). Administration of capsaicin with QX-314 also significantly reduced, but did not eliminate, 
scratching produced by subsequent injections of chloroquine (P < 0.01; Figure 5.6b), even 
though only a third of chloroquine neurons were capsaicin sensitive (Figure 5.4e), implying 
that the TRPV1+ subset of chloroquine- sensitive neurons may have a particularly prominent 
role in eliciting behavioral itch responses."
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Figure 5.5 - Venn representation of relative populations of trigeminal and DRG neurons defined by their 
calcium responses to histamine and chloroquine. (a) Histamine (100 μM) activated 10 of 208 trigeminal 
neurons, while 9 responded to 100 μM chloroquine. Among histamine-activated cells 8 of 10 responded 
to histamine but not chloroquine. For chloroquine-responsive neurons, 7 of 9 responded to chloroquine 
alone. 2 cells responded to both histamine and chloroquine. (b) Among 417 cultured DRG neurons, 32 
cells responded 50 μM histamine and 34 were activated by 1 mM chloroquine. Among histamine 
responsive cells, 27 of 32 responded to histamine alone. Chloroquine, but not histamine, activated 29 of 
34 chloroquine responders. 5 cells responded to histamine and chloroquine."
Chloroquine-evoked scratching was virtually abolished 30 min after injection of QX-314 
together with AITC (Figure 5.6b). In contrast, injection of QX-314 with AITC did not reduce 
subsequent histamine-evoked scratching (Figure 5.6a). In summary, chloroquine-evoked 
scratching is effectively blocked when TRPA1+ (AITC responsive) fibers are electrically 
silenced. Histamine-evoked scratching, on the contrary, is largely abolished when TRPV1+ 
fibers are electrically silenced, but is unaffected when TRPA1+ (AITC responsive) fibers are 
blocked. Histamine itch is predominantly associated with TRPV1+ pruriceptor fibers, and non-
histamine itch is associated with TRPA1+ fibers."
"
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Figure 5.6 - Selective silencing of nociceptor populations differentially inhibits histamine itch and non-
histamine itch. (a and b) Cheek scratching (itch) following intradermal test injection of histamine (100 µg 
per 10 µl) alone (n = 6 mice, a) and chloroquine (CQ, 50 µg per 10 µl) alone (n = 6–7 mice, b) 30 min 
after a conditioning injection of vehicle (0.9% NaCl, 20 µl) or 1% QX-314 together with capsaicin or 
AITC. P values represent comparison to vehicle (white column) value (not significant, P > 0.05; **P < 
0.01, ***P < 0.001). Error bars represent s.e.m."
DISCUSSION"
We selectively inhibited pain- and itch-related behaviors by targeting the membrane-
impermeant sodium channel blocker QX-314 into peripheral axon terminals of distinct 
populations of trigeminal pruriceptors or nociceptors. The specific population silenced was 
determined by the pattern of activation of particular large pore channels by different 
pruritogens or algogens; TRPV1 for capsaicin and histamine, TRPA1 for AITC and 
chloroquine. Our approach differs from interventions that only block a particular receptor (for 
example, H1R and H4R)33 or channel (for example, TRPA1)34 in that it targets action potential 
generation and conduction of the activated axon, and differs from genetic targeted ablation of 
different sensory neuronal subtypes35 in that it is temporary, with no known compensatory 
changes."
Using this selective silencing strategy, we found that the fibers that mediate histamine and 
non-histamine itch are functionally separable. Our in vitro data confirm the presence of adult 
sensory neurons that respond only to histamine or only to chloroquine."
Separate afferent lines have been described for histamine and cowhage itch16,36 and a distinct 
non-histamine itch pathway activated by β-alanine17. Our data support separate functional 
pathways for histamine itch and itch mediated by the MrgprA3 and MrgprC11 ligands 
chloroquine and SLIGRL, respectively. The separation of these afferents on the basis of the 
silencing approach was defined for a broad range of pruritogen concentrations for targeting 
QX-314 into afferent terminals through activated TRP channels. At extremely high 
concentrations (>90 mM) of pruritogen in vivo, however, an overlap did occur between 
histamine and chloroquine populations. This cross-activation between the two populations 
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could be secondary to release of endogenous mediators from keratinocytes, mast cells or 
other non-neuronal cells activated secondary to high-dose pruritogen administration, or it 
could reflect a very limited sensitivity of the peripheral terminals of histaminergic pruriceptors 
to chloroquine and SLIGRL and of the non-histaminergic terminals to histamine. Given that the 
high concentrations of the opposing pruritogen required to co-activate the separate histamine 
or non-histamine responsive set of afferents are unlikely to be found in most natural 
conditions29,30, we consider it probable that the two sets are functionally distinct and normally 
act independently."
Our calcium imaging data also confirm the existence of distinct trigeminal and DRG neuron 
populations that respond to either chloroquine or histamine at a range of doses in adult mice. 
Prior in vitro experiments have shown that MrgprA3 lineage DRG neurons in juvenile (4 week 
old) mice respond both to chloroquine (1 mM) and histamine (50 µM)6. Similarly, ablation of 
MrgprA3+ neurons in 5-week-old mice substantially attenuates both chloroquine- and 
histamine-evoked scratching behavior15. However, a recent study found that the proportion of 
DRG neurons responding to both histamine and chloroquine was markedly less in 7–9-week-
old mice compared with 3–4-week-old mice18. We interpret these collective data as suggesting 
that, in adult (2–4 month old) mice, Mrgpra3+ neurons are likely composed of pruriceptors with 
a differential sensitivity to, but not absolute selectivity for, chloroquine, and that these afferents 
normally contribute primarily to non-histaminergic itch. Microneurographic studies in humans 
have identified a distinct set of histamine-insensitive fibers that are activated during cowhage-
evoked itch16. The finding that cowhage spicules activate MrgprA3+ neurons suggests that a 
common pathway may mediate chloroquine and cowhage itch15. However, cowhage spicules 
 97
act nondiscriminatively on many nociceptor subtypes and may instead trigger itch 
nonspecifically through focal activation of superficial nociceptor terminals37."
H1R and MrgprA3 receptors rely on downstream activation of TRPV1 or TRPA1 channels, 
respectively, to generate itch behavior11,12,14, which is somewhat counterintuitive, as these 
TRP channels are also activated by algogens (capsaicin and AITC) that normally produce 
pain. This raises questions as to whether there are different subsets of TRPV1+ or TRPA1+ 
neurons involved in processing pain or itch and why pain normally predominates. Our data 
indicate that histamine itch is mediated by TRPV1+ fibers that do not express appreciable 
levels of TRPA1, as histamine itch is inhibited by silencing capsaicin-activated fibers, but not 
by silencing AITC-activated fibers. This correlates with the coincidence of capsaicin and 
histamine responsiveness in most histamine-responsive trigeminal neurons. In contrast, 
chloroquine itch appears to be mediated mainly by TRPA1+ fibers. However, using capsaicin-
induced silencing and trigeminal neuron calcium imaging, we found that a subset of these 
fibers also co-expressed TRPV1. TRPV1 is therefore broadly expressed in nociceptors and 
both histaminergic and non- histaminergic pruriceptors."
Our findings suggest that primary afferent itch-generating neurons encode functionally distinct 
histamine and chloroquine itch pathways. In addition to revealing modality specificity and 
functional specialization of somatosensory afferents, our findings could also help to direct 
development of new treatments for itch. Administration of QX-314 may be an effective 
treatment for pruritus caused by either histamine or non-histamine pruritogens if they are 
associated with sufficient activation of TRPV1 or TRPA1. Alternatively, given that large-pore 
channels are present in both histamine- and chloroquine-sensitive pruriceptors, broadly 
targeting QX-314 into these fibers via co-activation of both TRPV1 and TRPA1 channels, for 
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example, by using a non-pungent TRPV1/TRPA1 co-activator23,24,43, may have therapeutic 
promise for preventing or blocking both histamine-evoked itch and histamine-independent itch, 
albeit at the expense of also producing analgesia."
"
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Conclusion!""
The research I have been privileged to participate in has broadly focused on the 
mechanisms and pathways of nociception. Nociception as a biological process is still quite 
mysterious in many ways. Additional tools, compounds, molecules and approaches are 
necessary to delve further into these mysteries. It is a process I have been enjoyed being a 
part of. "
"
In spite of clinical and experimental setbacks to developing antagonists to TRPV1, TRPV1 is 
still an important target for analgesia-development. Using an innovative method to look at 
TRPV1 sensitization could open another pathway to efficiently finding modulators of TRPV1 
sensitization. Using the FDSS7000EX (Hamamatsu) for examining TRPV1 sensitization 
makes it possible to look at many different compounds and examine these in a more native 
environment than in heterologous expression systems. I think there is much promise in the 
modulation of TRPV1 sensitization/desensitization if competitive antagonists of the heat 
modality are not as safe clinically. I also think non-competitive antagonists could play a 
valuable role in developing TRPV1-targeted analgesia. Fortunately, this research has led to 
many additional questions to ask about TRPV1 function in general. Showing that TRPV1 is 
sensitized by bortezomib, a proteasome inhibitor could lead to understanding about TRPV1 
biology if it doesn’t lead to analgesic potential in the clinic. So, there are broad implications 
about the role of TRPV1 still to follow up on. Is TRPV1 actively contributing to nerve damage 
following bortezomib treatment? Is TRPV1 merely a sensor for the damage that is occurring, 
or is it both? TRPV1 sensitization is still a critically important research topic. "
"
Teasing apart the pathways in itch using the trigeminal system has shown that itch fibers 
responsive to chloroquine are distinct from those fibers which respond to histamine. This is 
an important contribution to the labeled-line debate as well as a nice demonstration of the 
utility of the QX-314 silencing strategy in probing biology. By examining cultured trigeminal 
neurons, I confirmed that these cells are largely separate and that they are preferentially 
connected with TRPA1 (chloroquine) or TRPV1 (histamine). Not only does this study 
demonstrate the anatomical separation of these cells, but by so doing exhibits a potential 
approach to treating pruritic conditions. QX-314 will only enter those neurons which are 
actively firing through TRPA1 or TRPV1, keeping its action specific. "
"
The study on Optovin was a particularly unique opportunity. The pharmacological tools for 
TRPA1 are still far behind those for TRPV1, although in the particular case of optovin, 
TRPA1 has the advantage. Optovin is a light-sensitive TRPA1 activator. We showed that it 
works on TRPA1 expressed in HEK cells, that it is not operative in TRPA1 knockout cells, 
and that it likely interacts with TRPA1 on a site similar to where mustard oil acts using a 3CK 
TRPA1 mutant. The potential benefits of this tool are just waiting to be explored. "
"
There are additional variations on the themes mentioned in this dissertation that are worth 
mentioning. An additional project that I worked on was the role of endothelin-1 in the 
sensitization of P2X receptors, utilizing a similar approach that we are using in the 
hamamatsu-based experiments. Additionally, our lab has culturing nociceptors from mouse-
embryonic fibroblasts. The TRPA1 and TRPV1 responses of these cells are quite similar to 
primary sensory neurons, which is quite remarkable. It is conceivable that we should be able 
to culture enough cells to replace our primary sensory neurons in a 384-well plate and even 
examine human-derived nociceptors for tendencies to be sensitized or desensitized in a 
 103
very interesting and novel model of nociception. In the meantime, we are making attempts to 
increase the efficiency of our sensitization models in the high-throughput system by utilizing 
GCaMP3-loxp X NaV1.8-cre animals to either look at in vivo sensitization of TRPV1 or 
increase the signal in our setup relative to noise in the absence of dyes."
"
Our work on TRPV1 sensitization in an unbiased high-throughput manner is a unique 
approach. We focus on one phenotypic outcome in native cells after manipulating various 
signaling pathways with bioactive molecules. There are still many other leads to follow up on 
and more thoroughly analyze. But in all cases, we are able to look backwards to begin to 
paint a more solid picture of the nodes and pathways leading to sensitization of TRPV1 in 
primary sensory neurons. 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Supplementary Figure 2.1 - Demonstration of raw data from FDSS 7000EX apparatus. (A) Raw 
activation of individual wells. Orange arrow indicates the addition of either 30 µM PGE2 (red line) or 
vehicle control (black). The blue arrow indicates the addition of 100 nM capsaicin. (B) Same data as in 
(A) only normalized by the first fluorescence value of each well (Ratio - Xn/X1). (C) Showing a closeup of 
the ratio response with the addition of 100 nM capsaicin where the ratio measurement is set to prior to 
the addition of the compound. (D) A closeup of the ratio response where the ratio standard denominator 
is adjusted to the 10 minute mark (600000 ms). 
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Supplementary Figure 2.2 - Calculation of Z-scores from raw data in FDSS 7000EX apparatus. (A) 
Calculated area under the curve for 60 second time period from the beginning of uniform addition of 
capsaicin (100 nM) to each well, some treated, some untreated. Showing mean and standard error. (B) 
Concentration response curve for capsaicin following 10 minute treatment with PGE2 or HBSS (Control) 
demonstrating increased response at 100 nM and 1 µM capsaicin. (C) Z-score calculated by using area 
under the curve showing the optimal zone of capsaicin concentration for the experiment to be between 
100 nM and 1 µM.
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Supplementary Figure 3.1 - Top hits from BioMol screen for TRPV1 sensitization. All compounds are 
sorted by Fisher’s unprotected LSD test, all with P values < 0.05. Prostaglandin E2 is a positive control. 
Different mechanistic and therapeutic classes of compounds are represented by colored bars.
